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Primary sclerosing cholangitis (PSC), is a chronic cholestatic disease that causes bile duct 
inflammation and fibrosis, and results in end-stage liver disease and reduced life expectancy. 
Therefore, an effective treatment for PSC is needed. Previously we identified specific Wnt proteins 
(Wnt7a, a canonical signaling ligand, and Wnt7b, a noncanonical signaling ligands) upregulated 
in the cholangiocytes during cholestatic liver injury and found mice lacking Wnt secretion from 
hepatocytes and cholangiocytes showed fewer hepatocytes expressing cholangiocyte markers, 
proliferating cholangiocytes, and high mortality in response to DDC diet. These findings led us to 
two hypotheses: 1) Canonical Wnt/β-catenin signaling induces hepatocyte-to-cholangiocyte 
transdifferentiation, which could alleviate cholestatic injury caused by PSC, and 2) Wnt7b induces 
cholangiocyte proliferation, which if knocked out would induce more severe cholestatic injury 
caused by PSC. After testing these hypotheses, we found that β-catenin signaling does induce 
hepatocyte-to-cholangiocyte reprogramming, thereby alleviating biliary injury. We also found that 
mice lacking Wnt7b in only the cholangiocytes, and mice lacking Wnt7b in both hepatocyte and 
cholangiocyte compartments did in fact have decreased cholangiocyte proliferation, but this did 
not result in increased biliary injury. Instead, this inability of the cholangiocytes to proliferate 
promoted hepatocytes to adopt a cholangiocyte-like phenotype, which resulted in the alleviation 
of cholestatic injury. Overall, our work has elucidated two methods to induce hepatocyte-to-
cholangiocyte transdifferentiation which could be used to establish a groundwork for potential 
PSC treatments. 
 v 
Table of Contents 
Preface ......................................................................................................................................... xvi 
1.0 Introduction ............................................................................................................................. 1 
1.1 Wnt Signaling Pathways ................................................................................................ 2 
1.1.1 Canonical Wnt/β-catenin Signaling ....................................................................2 
1.1.2 β-catenin Activity Independent of Wnt Signaling .............................................4 
1.1.2.1 PKA-Driven β-catenin Signaling ............................................................ 5 
1.1.2.2 β-catenin in Adherens Junctions ............................................................ 6 
1.1.3 Non-Canonical Wnt Signaling ............................................................................7 
1.1.4 Wnt Ligands in Liver ...........................................................................................8 
1.1.4.1 Wnt7b in the Liver ................................................................................... 9 
1.1.5 Wnt Signaling in Liver Development and Regeneration ................................10 
1.2 Biliary System ............................................................................................................... 12 
1.2.1 Physiology and Function of Cholangiocytes ....................................................13 
1.2.2 Cholangiocytes in Development ........................................................................15 
1.2.3 Bile Acid Synthesis and Transport in the Liver ..............................................16 
1.3 Biliary Injury and Regeneration ................................................................................. 17 
1.3.1 Intrahepatic Cholestatic Liver Disease ............................................................17 
1.3.1.1 Primary Sclerosing Cholangitis ............................................................ 17 
1.3.2 Ductular Proliferation in Cholestasis ...............................................................18 
1.3.2.1 Wnt Driven Cholangiocyte Proliferation During Cholestasis ........... 19 
1.3.3 Activated Cholangiocytes in Inflammation and Fibrosis ...............................20 
 vi 
1.3.4 Ductular Reaction ..............................................................................................21 
1.3.5 Murine Models of Primary Sclerosing Cholangitis ........................................22 
1.3.5.1 DDC as a Model of PSC ........................................................................ 22 
1.3.5.2 Mdr2 KO as a Model of PSC ................................................................ 24 
1.4 Hepatocyte-to-Cholangiocyte Transdifferentiation .................................................. 25 
1.4.1 Canonical Wnt Signaling in Hepatocyte-to-Cholangiocyte 
Transdifferentiation ....................................................................................................27 
1.4.2 Fate of Cholangiocyte-Like-Hepatocytes .........................................................28 
1.4.3 GC-1 as a Potential Driver of Hepatocyte-to-Cholangiocyte 
Transdifferentiation ....................................................................................................30 
2.0 The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse 
Model of Hepatic Cholestasis ..................................................................................................... 31 
2.1 Paper Summary ............................................................................................................ 31 
2.2 Background ................................................................................................................... 32 
2.3 Materials and Methods ................................................................................................ 34 
2.3.1 Animal Model .....................................................................................................34 
2.3.2 Serum Biochemistry ...........................................................................................35 
2.3.3 Immunohistochemical Analysis ........................................................................35 
2.3.4 Protein Extraction and Western Blot Analysis ...............................................37 
2.3.5 Quantitative Real-Time PCR ............................................................................37 
2.3.6 Measurement of Bile Acids ................................................................................39 
2.3.7 Statistical Analysis .............................................................................................39 
2.4 Results ............................................................................................................................ 40 
 vii 
2.4.1 Biliary Injury Is Decreased in KO after Short-Term GC-1 Diet...................40 
2.4.2 Fibrosis and Ductular Response Are Equivalent in KO Mice Fed GC-1 .....42 
2.4.3 GC-1 Alters the Amount and Location of BAs in Mdr2 KO Mice through 
Differential Regulation of Hepatic BA Transporters and Synthesis Enzymes ......45 
2.4.4 GC-1 Neither Induces Hepatocyte Proliferation nor Inhibits Cholangiocyte 
Proliferation in Mdr2 KO Mice .................................................................................53 
2.4.5 GC-1 Does Not Activate β-Catenin in Mdr2 KO Mice ...................................54 
2.4.6 TRβ Expression Is Decreased in Mdr2 KO, Resulting in a Blunted Response 
to GC-1 .........................................................................................................................56 
2.5 Discussion ...................................................................................................................... 57 
3.0 Determining the Effects of Wnt Signaling in the Alleviation of Cholestasis Via the 
Promotion of Hepatocyte Transdifferentiation ........................................................................ 61 
3.1 Paper Summary ............................................................................................................ 61 
3.2 Background ................................................................................................................... 62 
3.3 Materials and Methods ................................................................................................ 63 
3.3.1 Animal Model .....................................................................................................63 
3.3.2 Serum Biochemistry ...........................................................................................65 
3.3.3 Bile Flow Analysis ..............................................................................................66 
3.3.4 Hepatocyte Isolation and Roller Bottle Organoid Culture ............................66 
3.3.4.1 Composition of the MGM Cell Culture Medium................................ 66 
3.3.5 Immunohistochemical Analysis ........................................................................67 
3.3.6 Immunofluorescence Staining ...........................................................................67 
3.3.7 Quantitative Real-Time PCR ............................................................................68 
 viii 
3.3.8 Diet Comparison Study .....................................................................................69 
3.3.9 Statistical Analysis .............................................................................................69 
3.4 Results ............................................................................................................................ 70 
3.4.1 After 1 Month of Bio-Serv DDC exposure TG mice have more cholangiocyte 
marker expressing hepatocytes than WT mice ........................................................70 
3.4.2 Mouse Hepatocytes Reprogram to Cholangiocyte in In Vitro Organoid 
Models ..........................................................................................................................72 
3.4.3 S45D Mice exposed to Bio-Serv DDC Diet for 2 Months have Increased Bile 
Flow ..............................................................................................................................73 
3.4.4 Biliary Injury Improves Over Time in Mice Fed DDC Diet Long-Term .....75 
3.4.5 DDC Diet Exposure Promotes Increased Hepatocyte Reprogramming in 
S45D Transgenic Mice ................................................................................................77 
3.4.6 DDC Diet Producers Induce Differing Levels of Biliary Injury in ROSA and 
S45D Mice ....................................................................................................................80 
3.5 Discussion ...................................................................................................................... 81 
4.0 Wnt7b Regulates Cholangiocyte Proliferation and Function During Murine 
Cholestasis ................................................................................................................................... 87 
4.1 Paper Summary ............................................................................................................ 87 
4.2 Background ................................................................................................................... 88 
4.3 Materials and Methods ................................................................................................ 90 
4.3.1 Cell Lines, Transfection, and Luciferase Assay ..............................................90 
4.3.2 Animal Models ....................................................................................................91 
4.3.3 Serum Biochemistry ...........................................................................................92 
 ix 
4.3.4 Immunohistochemical Analysis ........................................................................92 
4.3.5 Quantitative Real-Time PCR ............................................................................94 
4.3.6 Protein Extraction and Western Blot Analysis ...............................................95 
4.3.7 Confocal microscopy and image analysis of mRNA expression by RNAscope
 .......................................................................................................................................95 
4.3.8 Statistical Analysis .............................................................................................97 
4.4 Results ............................................................................................................................ 97 
4.4.1 Overexpression of Wnt7b in cholangiocytes induces cell proliferation 
independent of β-catenin signaling in vitro ...............................................................97 
4.4.2 Overexpression of Wnt7b induces an inflammatory phenotype in cultured 
cholangiocytes ..............................................................................................................99 
4.4.3 Wnt7b deletion in vivo improves biliary injury after 1 month of DDC 
exposure .....................................................................................................................101 
4.4.4 Wnt7b knockout has no effect on parenchymal injury or fibrosis ..............105 
4.4.5 Wnt7b regulates cholangiocyte proliferation and ductular response in vivo
 .....................................................................................................................................107 
4.4.6 Wnt7b knockout promotes hepatocyte-to-cholangiocyte reprogramming .110 
4.4.7 β-catenin activation is increased in livers that lack Wnt7b in hepatocytes and 
cholangiocytes ............................................................................................................110 
4.5 Discussion .................................................................................................................... 112 
5.0 Concluding Remarks and General Discussion ................................................................. 117 
5.1 Significance ................................................................................................................. 117 
 x 
5.2 Future Directions: Wnt/β-catenin Driven Hepatocyte-to-Cholangiocyte 
Transdifferentiation ......................................................................................................... 118 
5.3 Future Directions: Wnt7b Driven Cholangiocyte Proliferation ............................ 119 
Bibliography .............................................................................................................................. 121 
 xi 
List of Tables 
Table 1. List of Primers Used for Quantitative RT-PCR Analysis in Section 2.0................. 38 
Table 2. List of Primers Used for Quantitative RT-PCR Analysis in Section 3.0................. 69 
Table 3. Primers used for quantitative RT-PCR analysis in Section 4.0 ............................... 94 
 
 xii 
List of Figures 
Figure 1. Schematic for Wnt Driven Bile Duct Regeneration .................................................. 2 
Figure 2. Canonical Wnt/β-Catenin Signaling ........................................................................... 4 
Figure 3. Non-Canonical Wnt Signaling Pathways ................................................................... 8 
Figure 4. Liver Zonation and the Biliary System..................................................................... 13 
Figure 5. How DDC works as a model of PSC ......................................................................... 23 
Figure 6. The type of injury drives the type of repair ............................................................. 25 
Figure 7. Hepatocyte-derived cholangiocyte incorporations into bile ducts ......................... 29 
Figure 8. GC-1 does not affect serum bilirubin or the liver weight/body weight (LW/BW) 
ratio of ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) 
mice........................................................................................................................................... 41 
Figure 9. Biliary injury improves in ATP binding cassette subfamily B member 4 (Abcb4−/−; 
Mdr2−/−) knockout (KO) mice at 2 and 4 weeks after GC-1, at the expense of hepatic injury
................................................................................................................................................... 41 
Figure 10. GC-1 treatment induces hepatocyte death in vivo ................................................. 42 
Figure 11. ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) 
mice treated with GC-1 have decreased liver fibrosis but similar ductular response 
compared with KO mice on normal diet............................................................................... 45 
Figure 12. Sex-determining region Y-box transcription factor 9 (Sox9) 
immunohistochemistry shows that ATP binding cassette subfamily B member 4 (Abcb4−/−; 
Mdr2−/−) knockout (KO) mice and KO mice treated with GC-1 have increased ductular 
 xiii 
reaction compared with both untreated wild-type (WT) mice and WT mice treated with 
GC-1 at 2 and 4 weeks ............................................................................................................ 45 
Figure 13. Bile acid excretion is dysregulated in ATP binding cassette subfamily B member 
4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice on GC-1 diet, concomitant with altered nuclear 
receptor and cytochrome P450 (Cyp) gene expression ........................................................ 47 
Figure 14. Bile acid transporter genes are altered after GC-1 diet, which leads to toxic bile 
retention in hepatocytes .......................................................................................................... 50 
Figure 15. Schematic of changes in bile acid transporters and detoxification enzymes in ATP 
binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice on GC-
1 after 2 and 4 weeks of diet exposure compared with mice on normal diet ..................... 52 
Figure 16. GC-1 has no effect on either hepatocyte or cholangiocyte proliferation in ATP 
binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice .......... 54 
Figure 17. β-Catenin is not activated by GC-1 in ATP binding cassette subfamily B member 
4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice ...................................................................... 55 
Figure 18. GC-1 induces deiodinase expression to a lesser extent in ATP binding cassette 
subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) livers than in wild-type (WT) 
livers, due to decreased expression of thyroid hormone receptor β (TRβ) receptor ........ 56 
Figure 19. After 1 Month of Bio-Serv DDC exposure TG mice have more cholangiocyte 
marker expressing hepatocytes, but similar biliary and hepati injury compared to WT 
mice exposed to DDC diet....................................................................................................... 71 
Figure 20.Cholangiocytes present in hepatic organoids are hepatocyte-derived .................. 73 
Figure 21. Bile flow is increased in S45D mice after 2 months of Bio-Serv DDC diet exposure
................................................................................................................................................... 74 
 xiv 
Figure 22. S45D mice on Bio-Serv DDC diet for 2 months have hepatocyte-derived 
cholagniocytes present ............................................................................................................ 75 
Figure 23. Biliary injury improves over time, but hepatic injury remains high in both ROSA 
and S45D mice fed DDC diet.................................................................................................. 77 
Figure 24. As DDC diet exposure increases S45D mice have more hepatocyte-derived 
choalginocytes present than ROSA mice .............................................................................. 79 
Figure 25. After 2 months of exposure to DDC diets from different producers ROSA and 
S45D mice have differing levels of biliary injury, but comparable levels of hepatic injury
................................................................................................................................................... 81 
Figure 26. Transgenic mice have decreased biliary injury compared to WT mice after 150 
days of DDC diet exposure ..................................................................................................... 83 
Figure 27. Quantitative RT-PCR analysis demonstrates Wnt7b overexpression and β-catenin 
suppression in SMCCs ............................................................................................................ 98 
Figure 28. Overexpression of Wnt7B in SMCC culture induces cells proliferation 
independent of β-catenin activity........................................................................................... 98 
Figure 29. Wnt7b overexpression in cholangiocyte cell culture promotes upregulation of 
commonly altered cytokines ................................................................................................. 101 
Figure 30. Confirmation of Wnt7b depletion in cholangiocyte-specific and liver-specific KO
................................................................................................................................................. 102 
Figure 31. RNAscope for Wnt7b confirms deletion in CC KO ............................................ 103 
Figure 32. Blood serum results indicate Wnt7b knockout improves biliary injury after 1 
month of DDC exposure ....................................................................................................... 105 
Figure 33. Wnt7b KO has no effect on ductular response and fibrosis ............................... 107 
 xv 
Figure 34. Wnt7b knockout inhibits cholangiocyte proliferation ........................................ 108 
Figure 35. Wnt7b knockout suppresses ductular reaction and promotes hepatocyte 
expression of cholangiocyte markers .................................................................................. 109 
Figure 36. Wnt7a expression and β-catenin activity is upregulated in mice fed DDC diet 111 
Figure 37. Schematic of how Wnt7b KO might promote hepatocyte-to-cholangiocyte 
reprogramming ..................................................................................................................... 114 
 xvi 
Preface 
Deciding to pursue my PhD was an easy decision to make, but completing graduate school 
has been the most challenging thing I’ve ever done. I would have never made it this far without 
the support of my friends and family. First and foremost, I would like to thank my family for 
constantly encouraging me to pursue my passions and empowering me to do so. Especially my 
mother and sister for always being there for me and willing to let me talk about my research, even 
though they might not understand a single word I’m saying. I would also like to thank all of the 
friends I have made while at the University of Pittsburgh. They have provided me with a life 
outside of lab, memories I will cherish forever, and a support network I will always have no matter 
how far apart we end up. Tuesday dinners, dungeons and dragons, and camping will never be same 
without them.  
I would especially like to thank the members of the Nejak-Bowen lab, who created the best 
work environment ever. Pam for helping me throughout my time in the lab, always being a great 
sounding board for anything and everything, helping me come up with appropriate controls when 
needed, and for knowing everything there is to know about Pittsburgh and educating me as much 
as she could. Lizzie, Mary, and Anu for always being down to get lunch and bubble tea and for 
making our lab even more fun as they joined. It’s thanks to all of their help and advice that I have 
been able to get to this point. I have always been happy to come to work and you all have made it 
all the better. I would also like to thank my thesis committee members for their support and insight 
in my scientific endeavors, without their guidance my project would not be where it is today. I 
would like to thank Dr. Monga for helping me throughout my graduate career. From when I first 
joined Dr. Nejak-Bowen’s lab by letting me join his lab’s weekly lab meeting when our lab was 
 xvii 
only three people, to giving me advice on where to postdoc, his insight and knowledge have been 
greatly valued and he has helped me to become the researcher I am today. 
Finally, I would like to thank Dr. Nejak-Bowen. She has been an incredible mentor 
throughout this process, and it is thanks to her guidance and support that I am the scientist I am 
today. She has always been supportive of both myself and my ideas and fostered my independence 
and critical thinking. She aided the growth of my career by encouraging me to submit abstracts, 
travel to, and present at conferences, apply for grants, and write papers. I can say without any 
doubt that my success as a graduate student has been a direct result of her outstanding mentorship. 
I may be Dr. Nejak-Bowen’s first graduate, but I know deep down that she will continue to help 
shape great future scientists and she will only get better with it as she gets more experience. 
Although my time in her lab is finishing up, I will continue to look to her for advice and mentorship 




The liver performs a multitude of functions vital to homeostasis, making it crucial to 
survival. The biliary system within the liver also plays a crucial role in hepatic health and function. 
Without the cholangiocytes within the biliary system, bile would not be modified or transported 
out of the liver, damaging to the liver. Therefore, it is crucial for the liver and the biliary system 
to possess the ability to regenerate upon injury. Both the liver and the biliary system are capable 
of regenerating through two methods: transdifferentiation and proliferation. However, during 
chronic cholestatic diseases, such as primary sclerosing cholangitis (PSC), the ability of the biliary 
system to repair or regenerate is severely impaired. This dissertation focuses on the role of Wnt 
signaling in the regeneration of injured bile ducts; canonical Wnt signaling induces hepatocyte-to-
cholangiocyte transdifferentiation (Aim 1) and non-canonical Wnt signaling induces healthy 
cholangiocyte proliferation (Aim 2) (Figure 1). This study will define the roles of both canonical 
and non-canonical Wnt signaling in bile duct regeneration in cholestatic liver disease and these 




Figure 1. Schematic for Wnt Driven Bile Duct Regeneration 
 Bile Duct Regeneration can occur through two different means: 1) canonical Wnt/β-catenin signaling can indue 
hepatocyte-to-cholangiocyte transdifferentiation (Aim 1) or 2) non-canonical Wnt signaling can induce healthy 
cholangiocytes to proliferate (Aim 2). These newly generated cholangiocytes increase the healthy cholangiocyte 
population, leading to the formation of de novo bile duct channels, which could relieve cholestatic injury. 
1.1 Wnt Signaling Pathways  
1.1.1  Canonical Wnt/β-catenin Signaling 
The Wnt signaling pathway is a highly conserved pathway found in all phyla of the animal 
kingdom. The canonical Wnt pathway is centered on regulating and signaling through moderating 
the levels of β-catenin protein in cells. Canonical Wnt signaling is highly regulated and involved 
 3 
in multiple biological processes ranging from development to cancer. Signaling in the canonical 
Wnt/β-catenin pathway is mediated through Wnt ligands. Wnt ligands are part of a family of 
secreted glycoproteins that are relatively insoluble due to a hydrophobic lipid modification, 
palmitoylation, which is necessary for their function (1). Wnt ligands are palmitoylated by enzyme 
porcupine in the endoplasmic reticulum (2). Post palmitoylation, Wntless (Wls), a transmembrane 
protein that mediates protein trafficking between the Golgi apparatus and cell membrane, secretes 
the hydrophobic Wnts from the cell (3, 4).  
In the absence of Wnt ligands , β-catenin levels are kept low via degradation by a β-catenin 
destruction complex consisting of the proteins Axin, adenomatous polyposis coli (APC), Glycogen 
synthase kinase 3 (GSK3), and casein kinase 1α (CK1α) (5, 6) (Figure 2). The scaffold protein 
Axin brings together the destruction complex components, mediating the phosphorylation of β-
catenin by CK1α first at serine 45, followed by serine 33 and serine 37, and GSK3 phosphorylates 
threonine 41 (5, 7). Phosphorylated β-catenin is then recognized by β-transducin repeat-containing 
protein (βTrCP), a component of the E3 ubiquitin ligase complex, triggering the ubiquitination and 
proteasomal degradation of β-catenin (5, 8, 9) (Figure 2A).  
To activate the canonical Wnt/β-catenin pathway, a secreted Wnt ligand binds to a Frizzled 
receptor (Fz) and the co-receptor low-density lipoprotein receptor-related protein (LRP) 5 or 6 
(10-12). This binding of Wnt to its receptors mediates activation of the Wnt/β-catenin signaling 
pathway. The scaffolding protein Dishevelled (Dvl) is triggered to phosphorylate LRP5/6 (4, 13). 
Phosphorylated LRP5/6 then recruits Axin to the plasma membrane, removing Axin from the 
destruction complex (4, 13). This removal of Axin disrupts the β-catenin destruction complex, 
promoting stabilization and cytoplasmic levels of β-catenin to increase. β-catenin then translocates 
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to the nucleus where it forms a complex with T cell factor/lymphoid enhancer factor (TCF/LEF) 
transcription factors to mediate expression of target genes (14, 15) (Figure 2B).  
 
Figure 2. Canonical Wnt/β-Catenin Signaling 
(A) In the absence of Wnt β-catenin is phosphorylated by its destruction complex. This phosphorylation targets β-
catenin for proteasomal degradation by β-transducin repeat-containing protein (β-TrCP). (B) Wnt is released from a 
neighboring cell by cargo receptor Wntless. The Wnt protein binds to its receptor (Frizzled) and co-receptor (LRP5/6), 
triggering the scaffold protein Dishevelled (Dvl) to recruit Axin and the β-catenin destruction complex to the plasma 
β-catenin accumulates in the cytoplasm, and translocates to the nucleus to bind the T cell factor/lymphoid enhancer 
factor (TCF/LEF) family of transcription factor inducing target gene transcription. 
1.1.2 β-catenin Activity Independent of Wnt Signaling 
β-catenin is known to play integral roles in both gene transcription and the regulation and 
coordination of cell-cell adhesion. However, not all of the functions performed by β-catenin are 
driven by Wnt signaling. Epidermal growth factor (EGF), hepatocyte growth factor (HGF)/c-met, 
and Protein Kinase A (PKA) have also been shown to regulate β-catenin activity. EGF has been 
observed to activate β-catenin signaling to promote mesenchymal stem cell proliferation (16) and 
induce the extracellular-signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) 
pathway to phosphorylate LRP6, a co-receptor to Frizzled, to activate  β-catenin signaling during 
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bone and cartilage formation (17, 18). HGF/c-met’s activation of β-catenin is well studied in 
hepatoblastoma (19, 20). Pathologic activation of β-catenin via HGF/c-Met signaling is present in 
most tumors of hepatoblastoma and has been found to utilize a separate pool of β-catenin located 
at the inner surface of the cell membrane (21, 22).  
1.1.2.1 PKA-Driven β-catenin Signaling 
Like HGF/c-met activation of β-catenin, PKA induction of β-catenin activity is also known 
in the liver. Due to β-catenin’s dual function in both cell-cell adhesion and gene transcription, the 
protein has many sites at which it can be phosphorylated to designate whether β-catenin should 
active or degraded and where β-catenin should be localized in the cell (7, 9, 23, 24). Interestingly, 
there are also two sites of phosphorylation on the β-catenin protein that are known to be 
phosphorylated by PKA and are distinct sites from Wnt signaling and cell-cell adhesion 
phosphorylation sites (25-27). These PKA driven phosphorylation sites are Ser-552 and Ser-675, 
and phosphorylation of these novel sites prevents β-catenin from being degraded and increases its 
transcriptional activity (25-27).  
PKA-driven phosphorylation of Ser-675 and subsequent activation of β-catenin is known 
to play a couple roles in the liver. In conjunction with activated Ras-related C3 botulinum toxin 
substrate 1(Rac-1), PKA induced phosphorylation of β-catenin at Ser-675 has been shown to 
increase the motility of fibrocystin-defective cholangiocytes (28). Additionally, PKA driven 
phosphorylation of Ser-675 has been found to induce hepatocyte proliferation when the liver is 
exposed to thyroid hormone (T3) (29, 30). This proliferation was found to be promoted through β-
catenin’s induction of cyclin D1 expression (29, 30). 
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1.1.2.2 β-catenin in Adherens Junctions 
β-catenin is also involved in cell-cell adhesions as a component of adherens junctions. 
Adherens junctions are protein complexes that form subapical junctions that promote homotypic 
cell-cell adhesions in epithelial tissue (31). The main component of adhesion protein complexes is 
a class of transmembrane proteins called cadherins, which perform the extracellular interaction 
during cell-cell adhesion. E-cadherin is typically the cadherin protein found in adherens junctions. 
To mediate cell-cell adhesion the extracellular domain of E-cadherin forms calcium-dependent 
complexes with E-cadherin molecules of neighboring cells (32). β-catenin’s role in adherens 
junctions is to facilitate in anchoring E-cadherin to the actin skeleton. β-catenin acts as a bridge 
between E-cadherin and α-catenin, which binds directly to the actin cytoskeleton or to actin-
binding proteins (33, 34). Additionally, β-catenin facilitates the assembly of the adherence junction 
protein complex. β-catenin binds newly synthesized E-cadherin, which promotes E-cadherin’s 
delivery from the endoplasmic reticulum to the basal-lateral plasma membrane (35-37). β-catenin 
binding to E-cadherin also blocks a specific peptide sequence, which when exposed targets E-
cadherin for proteasomal degradation, protecting E-cadherin from being degraded (35, 38).  
However, β-catenin is not permanently integrated into adherens junctions. β-catenin can be 
phosphorylated to induce dissociation from the adherens junction. Specifically tyrosine 
phosphorylation of β-catenin at residues Y142, Y654, and Y670 by HGF/c-met activity, and Y654 
by epidermal growth factor receptor (EGFR) activity, and Src activity leads to the disassembly of 
the β-catenin from adherens junction to increase β-catenin available for other signaling pathways 
(21, 39-42). β-catenin may also play a role in tight junction formation in the blood-bile barrier, 
which prevent the mixing of bile in the biliary canaliculi with blood in the hepatic sinusoids. It 
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was found that liver-specific loss of β-catenin leads to intrahepatic cholestasis, defective bile 
canalicular morphology, and bile secretory defects (43-45).  
1.1.3 Non-Canonical Wnt Signaling 
Wnt ligands are also capable of signaling independent of β-catenin, or non-canonical Wnt 
signaling. Two well studied pathways in which Wnt acts independently of β-catenin are the planar 
cell polarity (PCP) pathway and the Wnt/calcium pathway. In the PCP pathway Wnt ligands bind 
to Frizzled and another co-receptor receptor tyrosine kinase-like orphan receptor 2 (Ror2) (46, 47) 
(Figure 3A). Dishevelled is then activated and recruited to the plasma membrane, leading to the 
activation of RhoA and Rac, Rho-family small GTPases. RhoA and Rac subsequently activate c-
Jun N-terminal kinase (JNK) and Rho-associated protein kinase (ROCK). The signaling from JNK 
and ROCK leads to modification of the actin cytoskeleton causing cytoskeletal rearrangement that 
allows for changes in cell polarity and cell migration (46, 48-50).  
The other non-canonical Wnt signaling pathway is the Wnt/calcium pathway (Figure 3B). 
Similar to the PCP pathway, a Wnt ligand binds to Frizzled receptor and co-receptor Ror2 (51, 
52). A complex consisting of Dishevelled and G-proteins is recruited to Frizzled and the complex 
phosphorylates Ror2 (53, 54). Phosphorylated Ror2 triggers membrane-bound enzyme 
phospholipase C (PLC) to activate membrane-bound phospholipid phosphatidyl inositol 4,5-
bisphosphate (PIP2) and increase cellular inositol 1,4,5-triphosphate (IP3), and 1,2 diacylglycerol 
(DAG). IP3, in turn, promotes increased intracellular calcium levels and DAG activates Protein 
Kinase C (PKC) (55). The increased calcium levels activate calcium-calmodulin dependent kinase 
II (CaMKII) and calcineurin (CaN), which regulate cell migration and cell proliferation (53, 56).  
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Figure 3. Non-Canonical Wnt Signaling Pathways 
(A) In the Planar Cell Polarity (PCP) pathway, Wnt ligands bind to a complex consisting of certain Frizzled receptors, 
Ror2, and Dishevelled. This triggers activation of Rac and JNK signaling, or RhoA and ROCK signaling to regulate 
cell polarity and migration. (B) In the Wnt/calcium pathway, Wnt ligands bind to Frizzled receptor and Ror2 co-
receptor. A tri-protein complex of Dishevelled and G-proteins is formed, and one of the G-proteins mediates 
phosphorylation of Ror2 co-receptor. Ror2 induces PLC to mediate PIP2’s generation IP3 and DAG. DAG activates 
PKC, and IP3 promotes increased intracellular calcium levels. Increased intracellular calcium levels activates CaMKII 
and CaN, which in turn regulate cell migration and proliferation. 
1.1.4 Wnt Ligands in Liver 
With multiple Wnt pathways, both canonical and non-canonical, it is not surprising there 
are multiple Wnt ligands. There are a total 19 of Wnt ligands, all of which are evolutionarily 
conserved across mammals (57, 58). With this many Wnts questions arise whether the 19 Wnt 
ligands have unique or redundant roles. Unique Wnt roles can be determined through 
developmental loss-of-function studies: Wnt1 and Wnt3 are involved in midbrain and cerebellum 
development, Wnt2 and Wnt7b play important roles in placental development, and Wnt10b and 
Wnt16 participate in bone development (59-65).  
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However, the role of specific Wnts in liver pathobiology are not well characterized. This 
lack of characterization is mostly due to the lack of robust Wnt antibodies and the ability of hepatic 
cell populations to compensate for when Wnts are mutated or lost by upregulating other Wnts that 
act analogously. Despite these difficulties some Wnts and their roles have been identified in the 
liver. During hepatic injury liver sinusoidal endothelial cells release Wnt2 which is required to 
promote liver regeneration (66). Once the liver is regenerated to its full size, Wnt5a is one of the 
factors that terminates liver regeneration (67). Wnt2 and Wnt9b are released from endothelial cells 
adjacent to central vein which aids in liver zonation (68). Finally, Wnt7b and Wnt10a have been 
found to promote cholangiocyte proliferation during cholestatic injury (69). 
1.1.4.1 Wnt7b in the Liver 
Apart from Wnt7b promoting cholangiocyte proliferation, not much more is known about 
it in context of the liver. Wnt7b is known to be a noncanonical Wnt ligand; however, this has only 
been determined in cell types outside of the liver, such as osteogenic cells, dendritic cells, 
pancreatic progenitor cells, and in prostate cancer (70-73). Wnt7b is also known to signal through 
canonical Wnt signaling in pancreatic adenocarcinoma, epithelial and vascular smooth muscle 
cells, renal cells, and during hippocampal synapse formation (74-77).  Interestingly a study did 
find that Wnt7b along with Wnt7a and Wnt10a were significantly upregulated during murine oval 
cell response, and β-catenin levels were also increased in the same cell compartments (78). These 
findings hint at one or more of the three Wnts found in this study being involved in canonical Wnt 
signaling pathway in oval cell response; however, studies have yet to completely determine 




1.1.5 Wnt Signaling in Liver Development and Regeneration 
Though the roles that specific Wnt ligands play in the liver is not completely known, Wnt 
signaling in the liver is pretty well understood. Wnt signaling, specifically canonical Wnt 
signaling, is known to play important roles in both liver development and regeneration. During 
development the endoderm consists of three parts: the foregut, from which the liver is derived, the 
midgut, and the hind gut. To begin liver formation, foregut development is initially inhibited via 
Wnt signaling from the mesoderm to the posterior endoderm to promote hindgut fate. The anterior 
endoderm simultaneously secretes Wnt antagonists to suppress Wnt/β-catenin signaling allowing 
the foregut to maintain its identity and to allow liver development (79, 80). Once the foregut is 
formed, canonical Wnt/β-catenin activation is required around embryonic day 8.5 (E8.5) for the 
liver specification. It has been noted that β-catenin’s removal from hepatoblasts during liver 
development in mice results in suboptimal liver development by E12 and fetal lethality by E17, 
which resulted from increased oxidative stress, hepatocyte apoptosis, and lack of hepatocyte 
growth (81). Postnatally, β-catenin activation is also important for hepatic cell proliferation for the 
continuation of liver development up to 20 days postnatal. This is known because β-catenin-null 
mice have lower liver weight to body weight ratios during their lifespan compared to wild type 
mice, while mice with hyperactivate β-catenin develop larger livers before one month of age due 
to the increased cell cycle entry and proliferation (82-84).  
Once the liver is developed it is capable of regenerating up to 70% of the organ if it is 
removed or acute hepatic injury occurs. This process of regeneration is mediated through the 
proliferation of existing differentiated hepatocytes (85). There are a few well studied models of liver 
injury and regeneration, however the two most prevalent models are two-thirds partial 
hepatectomy (PHx) model and acute liver failure from acetaminophen (APAP) overdose model. 
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During the PHx model two-thirds of a mouse or rat liver are removed. Within days of the removal, 
cellular hyperplasia and cellular hypertrophy takes place and the remaining lobes enlarge to replace 
liver mass that was lost (86). Wnt/β-catenin signaling is important to liver regeneration in this 
model. In rats, within minutes of PHx,  β-catenin expression is increased 2.5-fold followed by its 
rapid translocation to the nucleus, which helps to promote hepatocyte proliferation through target 
gene expression, such as cell-cycle regulator cyclin D1 (87, 88). Mice lacking β-catenin 
specifically in hepatocytes and mice lacking both Wnt co-receptors LRP5 and LRP6 displayed 
delayed regeneration 40 hours post PHx compared to WT mice (84, 89). However, there is a 
subsequent increase in regeneration in the β-catenin knockout mice three days post-PHX, 
indicating the activation of a compensatory signaling pathway (84). Therefore, Wnt/β-catenin 
signaling does play a role in liver regeneration post PHx; however, Wnt/β-catenin signaling is not 
necessary for regeneration post PHx, unlike liver development. 
Much like the PHx model, β-Catenin signaling is also required for regeneration after acute 
liver failure caused by APAP overdose. The APAP overdose model causes hepatotoxicity through 
the metabolization of APAP by cytochrome P450 enzymes, Cyp2e1 and Cyp1a2, which creates 
N-acetyl-p-benzoquinone imine, a toxic, reactive metabolite that covalently binds to cellular 
macromolecules, which induces hepatocyte death (90-92). Both CYP2E1 and CYP1A2 are target 
genes of β-catenin, so mice lacking β-catenin specifically in their hepatocytes are resistant to 
APAP-induced hepatotoxicity (93). However, β-catenin also promotes liver regeneration 
following APAP overdose. Liver-specific β-catenin knockout mice given APAP following 
induction of Cyp2e1 and Cyp1a2 activity presented with significant defects in hepatocyte 
proliferation following APAP-induced hepatic necrosis (90). Therefore, despite the protection 
lacking β-catenin offers hepatocytes during APAP overdose, it also hinders the hepatocytes’ ability 
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to proliferate and regenerate post APAP overdose, so β-catenin signaling is necessary for the 
liver’s ability to regenerate. 
1.2 Biliary System 
The biliary system is a 3-dimensional network of tubular structures that forms an almost 
tree-like shape with its branches connecting the hepatocellular parenchyma of the liver with the 
lumen of small intestine through its trunk. The main function of the biliary system is to transport 
bile from the liver to the small intestine to aid in digestion. Hepatocytes produce bile, which is 
secreted into the bile canaliculi, dilated intercellular spaces sealed by tight junctions between 
apical membranes of neighboring hepatocytes (94-96). The bile flows from canaliculi to the 
network of bile ducts, which are lined with cuboidal epithelial cells called cholangiocytes. Bile 
ducts anastomose into larger ductules, then larger ducts, which eventually form the common bile 






Figure 4. Liver Zonation and the Biliary System 
Left Image: The structure of a liver lobule consists of three zones. Zone 1 consists of the “portal triad”: the portal vein, 
bile ducts, (made of cholangiocyte), and hepatic artery. Oxygenated blood from the hepatic artery and portal vein 
mixes and flows through the hepatic sinusoids to the central vein, which is zone 3. Spaces between hepatocytes form 
the bile canaliculi, which transport bile excreted  from the hepatocytes in the opposite direction of blood flow to bile 
ducts. The interface between the end of the bile canaliculus and the start of the bile duct is known as the Canal of 
Hering. Right Image: The bile flows down through the ducts that grow in size and join together to form a branching 
network that ends in the common bile duct and the gallbladder, where bile is stored. 
1.2.1 Physiology and Function of Cholangiocytes 
Cholangiocytes are a highly dynamic, heterogeneous population of epithelial cells lining 
the three-dimensional network of bile ducts known as the biliary tree. Cholangiocytes differ in 
size, small cholangiocytes and large cholangiocytes, as well morphology that varies between the 
sizes: flattened or cuboidal small cholangiocytes less than 15 µm in diameter are in small sized, 
often in terminal ductules and the Canal of Hering, and large columnar cholangiocytes greater than 
15 µm in diameter are in large bile ducts (97-103). Small cholangiocytes also have a greater 
nuclear-to-cytoplasmic ratio than large cholangiocytes, which suggests small cholangiocytes may 
be less differentiated and have greater plasticity compared to large cholangiocytes (99, 104, 105). 
These differences compared to larger, more differentiated cholangiocyte implicate small 
cholangiocytes as a potential functional hepatobiliary progenitor cell population (105, 106). 
 14 
However, small cholangiocytes’ role as a hepatobiliary progenitor cell population has yet to 
determined experimentally. 
Regardless of their size, all cholangiocytes perform reabsorptive and secretory processes 
on the bile, which significantly modifies the volume and composition of the bile (105, 107). After 
a meal secretin is released, and it interacts with its G protein-coupled receptor localized on 
basolateral membrane of cholangiocytes, inducing an increase in intracellular cAMP levels (108-
111). The elevated cAMP subsequently stimulates the opening of cystic fibrosis transmembrane 
conductance regulator (CFTR), which activates the Cl-/ HCO3- anion exchanger 2 (AE2) causing 
the release of Cl- and HCO3- into the bile ducts (107, 109, 112, 113). In addition, transmembrane 
protein 16F (TMEM16A), a Ca2+-activated Cl- channel, can also promote HCO3- efflux (110, 114, 
115). Cholangiocytes also release ATP, which stimulates activation of Cl- channels and increases 
in Ca2+ concentration (116, 117). Biliary HCO3- release drives the movement of water through 
water channel aquaporin 1 (AQP1), resulting in increased biliary volume and enhanced choleresis 
(109, 118, 119). The maintenance of bile pH and volume through HCO3- and water release is very 
important as it creates an alkaline barrier, which prevents toxic bile acid accumulation and renders 
bile acids polar, de-protonated and membrane impermeable (120-122).  
 Cholangiocytes also modify bile through the absorption of bile acids, glucose, amino acids 
and ions. Bile acids, which are steroid acids, exist as either a free, unconjugated acids or acids 
conjugated to taurine or glycine. Unconjugated bile salts passively diffuse into cholangiocytes and 
are returned to hepatocytes through cholehepatic shunting (123, 124). Conjugated bile acids are 
absorbed from the bile through apical sodium-dependent bile salt transporter (ASBT) (125). 
Cholangiocyte express multidrug resistance protein 3 (MRP3) and multidrug resistance protein 4 
(MRP4), which efflux organic ions from the basolateral membrane (105, 126). Cholangiocytes 
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also express multidrug resistance 1 (MDR1), and Mdr1a in mice, which are ATP-dependent efflux 
pumps with extensive substrate specificity, including glucocorticoids, lipophilic cytotoxic drugs, 
peptide antibiotics, and Ca+2 channel blockers (105, 127). However, in cholangiocytes 
MDR1/Mdr1a are believed to prevent the accumulation of organic cations in cholangiocytes via 
the excretion of them back into bile (105). Therefore, cholangiocytes play a vital role in both the 
modification of bile composition and bile flow.  
1.2.2 Cholangiocytes in Development 
 Around E13, bipotential hepatoblasts begin to differentiate towards mature hepatocytes 
and cholangiocytes (128). By E15.5 the ductal plate begins to form as hepatoblasts with a 
cholangiocyte-like phenotype near the portal mesenchyme coalesce (129). The ductal plate will 
eventually give rise to primitive ductal structures that become the intrahepatic bile ducts. The 
complete adoption of hepatoblasts to a cholangiocyte phenotype is orchestrated through 
endothelial and mesenchymal cells within the portal tract expressing gradients of developmental 
morphogens such as Wnt/β-catenin, Notch, transforming growth factor-β (TGFβ) and fibroblast 
growth factor (FGF) (130-134). Interestingly, much like liver development, Wnt/β-catenin 
signaling is also required for bile duct development. Jagged1, a cell surface Notch ligand, also 
plays an important role in bile duct formation through its effects on both cell differentiation and 
tubulogenesis of bile ducts (129, 135, 136).  
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1.2.3  Bile Acid Synthesis and Transport in the Liver 
Bile acids are important for nutrient absorption in the intestines and biliary secretion of 
lipids, toxic metabolites, and xenobiotics. Synthesized in hepatocytes by the cytochrome P450 
(Cyp) enzymes, Cyp7a1 of the classic bile acid synthesis pathway and Cyp27 of the alternative 
synthesis pathway, bile acids are the end products of cholesterol catabolism (94, 137, 138). The 
major primary bile acids produced through these processes are cholic acid (CA) and 
chenodeoxycholic acid (CDCA), which are then conjugated with taurine or glycine rendering them 
more soluble, less cytotoxic, and easily secreted (139-141). Bile acids are excreted by the 
hepatocytes into the biliary canaliculi by apical transporters such as multidrug resistance-
associated protein-2 (MRP2) and the bile salt export pump (BSEP) (140). Once secreted the bile 
makes its way down through the bile ducts to the intestines to aid in nutrient absorption. In the 
intestines, about 15% of the CA and CDCA are converted to secondary bile acids, deoxycholic 
acid (DCA) and lithocholic acid (LCA) (137, 142). All bile acids, both primary and secondary, are 
recycled through a process called enterohepatic circulation, during which the bile acids are 
reabsorbed through the intestines, returned to the liver via portal blood circulation and basolateral 
uptake transporters, and reconjugated (137, 140, 143). This enterohepatic circulation of bile acids 
is an important process as it helps create a feedback control for bile acid synthesis (137, 140, 143). 
The liver is also very proficient in monitoring and maintaining hepatic bile acid levels; when bile 
acid levels increase, compensatory responses are activated such as decreased bile acid synthesis 
and uptake, and upregulation of bile acid metabolism and basolateral membrane export pumps 
(137, 140, 142, 144, 145). 
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1.3 Biliary Injury and Regeneration 
1.3.1 Intrahepatic Cholestatic Liver Disease 
Intrahepatic cholestatic liver diseases are often chronic, progressive diseases of the biliary 
tree. They can be either acquired or genetic, observed across all age groups, and have a variety of 
clinical features with a high degree of variability in prognosis and presentation between the 
diseases (146-148). The primary target of these diseases is typically the cholangiocyte cell 
population. Though cholestasis is not a disease itself, it is the common symptom of intrahepatic 
cholestatic liver diseases. Despite the variety of diseases all are diagnosed, both clinically and 
biochemically, through varying degrees of jaundice, pruritus, and elevated levels of serum alkaline 
phosphatase (ALP), γ-glutamyl transpeptidase (GGT), conjugated bilirubin, bile acids, and 
cholesterol (146-149). Despite our advances in diagnosing and understanding these diseases, 
unfortunately, to date there are no proven therapeutic treatments for the majority of these diseases. 
1.3.1.1 Primary Sclerosing Cholangitis 
One intrahepatic cholestatic disease of interest is primary sclerosing cholangitis (PSC). 
PSC is a rare, chronic, idiopathic, heterogeneous, cholestatic liver disease characterized 
histologically and biochemically by cholestasis and persistent, progressive biliary fibrosis and 
inflammation. Typically in PSC obliterative fibrosis and chronic inflammation of the intrahepatic 
bile duct leads to multifocal bile duct strictures, which causes bile stasis and chronic fibrosis (150-
153). These symptoms will continue to progress until patients with PSC develop cirrhosis, end‐
stage liver disease, and cholangiocarcinoma (150-153). Diagnostic criteria for PSC include 
increased levels of serum ALP persisting more than 6 months, cholangiographic findings of 
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multifocal bile-duct strictures, which are both used to monitor disease progression, and the 
exclusion of causes of secondary sclerosing cholangitis (154, 155). In general, PSC is slowly 
progressive with outcomes varying patient to patient. Currently there are no effective medical 
treatments for patients with PSC; however, if patients reach end-stage liver disease and they are 
eligible, they can receive a liver transplant (153, 156). Unfortunately, for patients who do require 
and receive a liver transplant, transplantation is not a cure, since up to 25% of patients will have 
recurrence of PSC within 10 years of receiving transplantation (155, 157-160). Therefore, an 
effective medical treatment for PSC that does not require transplantation would revolutionize the 
way these patients are treated. 
1.3.2 Ductular Proliferation in Cholestasis 
Cholangiocyte proliferation that occurs after biliary injury is categorized into three groups: 
“typical” proliferation, “atypical” proliferation, and oval cell proliferation. Of these types of 
proliferation, typical and atypical proliferation are known to take place during and after cholestatic 
injury. Typical cholangiocyte proliferation is confined to the portal areas and is a hyperplastic 
reaction, which induces an increase in the number of intrahepatic bile ducts (161, 162). During 
typical proliferation, the proliferating cholangiocytes create tubular structures with well-defined 
lumens, which form a three-dimensional network contributing to the bile ducts (161-164). This 
type of proliferation is observed in rodent models when exposed to -naphthylisothiocyanate 
(ANIT), carbon tetrachloride (CCl4), or lithocholic acid (LCA) in diet form, or after bile duct 
ligation, as well as in human patients during the early stages of chronic cholestatic liver disease 
and after acute obstructive cholestasis (163-171). 
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The second type of proliferation, atypical cholangiocyte proliferation, is irregular 
proliferation of the intrahepatic bile ducts which spread into the periportal and parenchymal 
regions of the liver (161, 162). Bile ducts formed through atypical proliferation are irregular and 
tortuous in shape, lack a well-defined lumen, and often functionally inefficient (161, 163, 172). 
This type of proliferation occurs in rat and mice models after chronic exposure to xenobiotics or 
chemicals such as 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), and is also commonly seen 
in human patients with prolonged cholestatic liver diseases such as primary biliary cholangitis 
(PBC) or PSC (163, 173, 174). Atypical proliferation can also involve an oval cell response, which 
is characterized by hyperplasia of bipotential cells with characteristics of both cholangiocytes and 
hepatocytes (175-177). Oval cell involvement in atypical proliferation has been observed in rodent 
models after chronic administration of DDC, D-galactosamine, and CCl4 and in human patients 
with alcoholic liver diseases, long chronic extrahepatic biliary obstruction, massive hepatic 
necrosis, and chronic cholestatic liver diseases, such as PSC and PBC (163, 170, 172, 178-180).  
Interestingly the role of the atypical ductules in cholangiopathies is controversial. During 
the early stages of injury, atypically proliferating cholangiocytes may contribute to hepatobiliary 
repair or protect against biliary insult (148). However, over time and as injury progresses 
proliferating atypical ductules can also release profibrotic and proinflammatory signals, which 
activate cells responsible for extracellular matrix deposition (181-183).  
1.3.2.1 Wnt Driven Cholangiocyte Proliferation During Cholestasis 
Wnt signaling is known to play many important roles in the liver and bile ducts, and some 
studies have found that specific may play certain roles during cholestatic injury. These study found 
that after DDC exposure or BDL, WT have increased expression of Wnt7a, Wnt7b and Wnt10a in 
EpCAM positive cells in the portal triad region of the liver compared to WT mice on normal diet 
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(69, 78). Wntless KO mice placed on DDC diet also had more hepatic damage, less ductular 
proliferation, and decreased survival compared to WT mice, which indicate these Wnts may play 
a protective role during cholestatic injury (69). Of these three Wnts, it was determined that Wnt7b 
and Wnt10a induce the proliferation of cholangiocytes in an autocrine fashion (69). These findings 
suggested Wnt7b and Wnt10a are a necessary signaling mechanism to promote cholangiocyte 
proliferation in cholestatic liver injury regardless of injury origin.  These roles for Wnt7b and 
Wnt10a are not unheard of, as both Wnts are known to be involved in proliferation, regeneration, 
and self-renewal in cell types outside of the liver (184-186). 
1.3.3 Activated Cholangiocytes in Inflammation and Fibrosis 
Often during intrahepatic cholestatic disease, cholangiocytes are activated through a 
variety of ways such as infections, xenobiotics, ischemia, and cholestasis (187, 188). However, in 
many cholangiopathies, including PSC, what activates cholangiocytes remains unknown. When a 
cholangiocyte is activated its proinflammatory and profibrotic secretions increase and along with 
its proliferation (182, 189). Activated cholangiocytes also recruit vascular, mesenchymal, and 
immune cells and facilitate the crosstalk between them, and if cholangiocyte activation becomes 
chronic biliary fibrosis and cholangiocarcinoma can develop (190-192). 
Recent findings indicate that this activated, secretory cholangiocyte phenotype is a result 
of cellular senescence prompted by stress and injury, which results in irreversible proliferative 
arrest (193-195). While in this state senescent cells are metabolically active, transitioning to 
cytokine and chemokine hypersecretory state, known as the senescence-associated secretory 
phenotype (SASP) (196, 197). SASP has been identified to be an important mechanism during 
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cholangiopathy development and progression, including PSC’s development and progression 
(195, 198, 199). 
1.3.4 Ductular Reaction 
During many cholangiopathies there is an expansion of cells that express cholangiocyte 
markers, believed to be either activated cholangiocytes or hepatic progenitor cells, from the 
periportal region and into the surrounding parenchyma. This cellular expansion is called ductular 
reaction and has been defined as “a reaction of ductular phenotype, possibly but not necessarily of 
ductular origin”(175). Though this definition leaves the cellular origin for ductular reaction up for 
debate, the activation of the ductular reaction is thought to be instigated by the impairment of 
cholangiocytes’ and hepatocytes’ ability to regenerate during liver injury. Ductular reaction is 
generally associated with infiltration of inflammatory cells, activation of myofibroblasts, and 
matrix deposition, and unless reversed, can lead to periportal fibrosis, ductopenia, and eventually 
biliary cirrhosis (200, 201). Ductular reaction is pathologically recognized as bile duct 
proliferation or hyperplasia and is identified in and often a hallmark of biliary disorders such as 
PSC, PBC, and biliary atresia (BA) (148, 175, 201). Interestingly, despite various liver conditions 
presenting with ductular reaction, the way ductular reaction presents differs depending on the 
disease. 
A recent study characterized ductular reaction in PSC and PBC, and they found that while 
ductular reaction is a prognostic marker for both conditions, the phenotype and activated signaling 
pathways different between the two diseases (202). PSC expressed lower levels of laminin and 
neurogenic locus notch homolog protein 1, but higher levels of wingless-related integration site 
(WNT) family pathway components, in the progenitor cell niche compared to PBC (202). This 
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increased expression of Wnt family pathway components during PSC, specifically in the 
progenitor cell niche, further indicates that Wnt signaling may play a role in cholangiocyte 
activation and proliferation or possible hepatocyte transdifferentiation. Another study used laser 
capture microdissection to isolate cells of the ductular reaction from patients with PSC or hepatitis 
C virus (HCV), then used high throughput RNA sequencing to analyze the differences between 
the cells (203). It was found that HCV has a more neo-angiogenesis signature and PSC has a more 
oxidative stress-related and pro-inflammatory gene expression signature (203). 
1.3.5 Murine Models of Primary Sclerosing Cholangitis 
Due to the poor understanding of PSC’s pathogenesis, well-characterized animal models 
of PSC are invaluable. Not only do these models provide opportunities to develop and understand 
novel pathogenetic concepts,s they also offer opportunities to study new treatment strategies. 
Currently there are a variety of rodent models of PSC that utilize gene knockout, chemicals, 
infectious agents, or a multitude of other methods (204).  
1.3.5.1 DDC as a Model of PSC 
A common chemical induced method of studying PSC is the 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) diet model. DDC disrupts heme biosynthesis through the inhibition 
ferrochelatase activity (Figure 5A), which causes an excess of porphyrin to build up in the liver 
(205). This porphyrin is then exported out of the hepatocytes into the bile ducts, where it forms 
porphyrin pigment plugs in the biliary tract obstructing the bile duct and leading to a multitude of 
PSC like symptoms. After DDC exposure mice develop bile duct injury, cholangiocytes with a 
reactive phenotype, and serum markers similar to those of cholestasis (173, 206, 207). The livers 
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develop pericholangitis, onion skin-type periductal fibrosis, ductular reaction, bile regurgitation, 
and consequently portal-portal bridging, all of which are common histological markers of PSC in 
patients (Figure 5B) (173, 204). Finally, mice exposed to DDC diet also have a down-regulation 
of Mrp2, impaired glutathione excretion, and segmental bile duct obstruction (173). All of these 
results are hallmarks for PSC in patients and are achieved within 4 weeks of initial diet exposure, 
which makes DDC diet an ideal rodent model for studying PSC. 
 
Figure 5. How DDC works as a model of PSC 
(A) DDC inhibits ferrochelatase from completing the final step of the heme biosynthesis pathway, which results in an 
accumulation of porphyrin in the liver. (B) Porphyrin is exported from the hepatocytes into the bile ducts which 
accumulates and creates porphyrin plugs that obstruct the bile ducts. This obstruction results in injury to the bile duct, 
bile regurgitation, periductular fibrosis, and ductular reaction. 
 
 24 
1.3.5.2 Mdr2 KO as a Model of PSC 
A common genetic knockout model for studying PSC is the multidrug resistance gene 
(Mdr2) (Abcb4) knockout (KO) mice (Mdr2(-/-)). Mdr2 is flippase that transports 
phosphatidylcholine from the hepatocytes into the biliary canaliculi; Mdr2 KO mice have a genetic 
disruption of the Mdr2 gene, causing a complete absence of phosphatidylcholine from bile (208-
210). Phosphatidylcholine is important to bile as it reduces the cellular toxicity of bile acids (211). 
Therefore, Mdr2 KO mice have more toxic bile compared to their WT counterparts and the toxic 
bile is what causes a PSC phenotype (212, 213). Mdr2 KO mice develop extrahepatic and 
intrahepatic biliary strictures, onion-skin-type periductal fibrosis, and focal fibrous obliteration of 
bile ducts, all of which are symptoms seen in PSC patients (212, 214, 215). Interestingly as these 
mice age their symptoms worsen, which makes PSC in Mdr2−/− mice a multistep process. 
Ultimately the mice develop a PSC phenotype that involves regurgitation of bile from leaky ducts 
into the portal tracts, which leads to the induction of periductal inflammation, followed by the 
activation of periductal fibrogenesis (214). All of these phenotypes then go onto to cause 
obliterative cholangitis that is owed to atrophy and death of bile duct epithelial cells, similar to 
PSC patients (214). Mdr2 KO mice also start to develop all of these symptoms as early as 2 weeks 
old and they become more pronounced with age, therefore the Mdr2 KO model is a very quick and 
effective model to study PSC (204, 212, 214).   
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1.4 Hepatocyte-to-Cholangiocyte Transdifferentiation 
The liver and the bile ducts can regenerate through two means: proliferation and 
transdifferentiation (Figure 6). This transdifferentiation typically only occurs during extreme 
hepatic or biliary injury. During this process, hepatocytes and cholangiocytes function as a type of 
“facultative stem cells,” and undergo reprogramming from one cell type to the other rescuing the 
failed regeneration (216, 217). In rodent models, mature hepatocytes transdifferentiate into biliary 
cells when there is extensive injury and resident cholangiocytes are unable to proliferate to 
adequately compensate for the injury (218-221). 
 
Figure 6. The type of injury drives the type of repair 
During mild or acute injury to the liver hepatocytes and cholangiocytes renew their respective cells populations 
through proliferation. However, during severe or chronic injury hepatocytes and cholangiocytes are able to 
transdifferentiate into the other cell type to help alleviate the injury. 
 
 
 In vitro studies using hepatic organoids derived from rats have been used to demonstrate 
hepatocyte-to-cholangiocyte transdifferentiation (222, 223) In one organoid study rats, which do 
not express Dipeptidyl Peptidase IV (DPPIV), were given retrorsine, which blocks hepatocyte 
proliferation, and transplanted with DPPIV-positive hepatocytes, resulting in livers with colonies 
of donor-derived DPPIV-positive hepatocytes. Organoid cultures were then derived from these 
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hybrid livers and cells resembling cholangiocytes were observed on the surface of the organoid 
culture (223). These cholangiocytes were also found to be DPPIV-positive, indicating they 
originated from hepatocyte (223). In another study, rat hepatocytes were cultured in medias 
containing various growth factors including hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 
stem cell factor (SCF), macrophage-stimulating protein (MSP), fibroblast growth factor-a (FGF-
a), fibroblast growth factor-b (FGF-b), and fibroblast growth factor-8b (FGF-8b) (222). Through 
this study it was determined that HGF and EGF are required to induce the phenotypic change of 
hepatocytes to cholangiocytes (222). 
This transdifferentiation has also been observed in vivo. By utilizing stain-tagging, 
hepatocyte-derived cholangiocyte were found in rats under conditions in which the biliary 
epithelium is incapable of repair due to toxic injury (220, 223). Genetic mouse models and lineage 
tracing has also shown that hepatocytes are capable of transdifferentiating to cholangiocytes under 
conditions that cause biliary toxicity and chronic liver injury (221, 224-226). Additionally, and 
most importantly, hepatocyte reprogramming has also been reported in human liver diseases. 
Hepatocytes from both pediatric and adult cholangiopathy patients have been observed to express 
the ductal marker OV-6 (227, 228). Additionally, hepatocytes express cholangiocyte-specific 
cytokeratins in patients with cholestasis (229-231). Finally patients with chronic biliary disease 
have been shown to have hepatocytes expressing biliary transcription factors (222, 224). 
Combined these results suggest that during biliary injury the number of hepatocytes expressing 
biliary markers increases over time; therefore, as cholestasis progresses, more and more 
hepatocytes compensate for the damage to and loss of the biliary epithelium.  
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1.4.1 Canonical Wnt Signaling in Hepatocyte-to-Cholangiocyte Transdifferentiation 
Though previous studies have shown the importance of HGF and EGF to hepatocyte-to-
cholangiocyte transdifferentiation, the role that Wnt signaling plays during this process has not 
been extensively studied. The same study determined that HGF and EGF are required for 
hepatocyte transdifferentiation in organoid culture also found that β-catenin and its downstream 
targets are upregulated in hepatic organoid cultures under conditions that promote hepatocyte 
reprogramming (222). This finding implicates a role for β-catenin in this transdifferentiation 
process. Wnt7A, which is expressed by cholangiocytes during cholestasis, has also been identified 
as a regulator of hepatocyte reprogramming (69). In vitro, Wnt7A was found to activate β-catenin 
and also induce hepatocytes to express biliary markers, such as SRY-related HMG box 
transcription factor 9 (Sox9) and epithelial cell adhesion molecule (EpCAM) (69). It has also been 
noted that mice transgenic (TG) for a non-degradable S45D-mutated β-catenin in the liver  showed 
an increased number of hepatocytes positive for A6, a biliary marker, compared to WT when 
subjected to DDC diet and cholestatic injury (180). This finding also coincided with a decreased 
in serum markers of biliary injury, alkaline phosphatase (ALP) and bilirubin levels, in S45D TG 
mice compared to WT mice exposed to DDC diet (180). The S45D TG mice were also found to 
have more hepatocytes expressing cholangiocyte markers, such as Sox9, after DDC exposed 
compared WT on DDC diet (180). Therefore, canonical Wnt signaling may play an important role 
in hepatocyte-to-cholangiocyte transdifferentiation. 
 28 
1.4.2 Fate of Cholangiocyte-Like-Hepatocytes 
Studies have shown that hepatocyte-derived cholangiocytes incorporate into biliary 
ductules, but no studies have shown the pattern through which these cells integrate (221, 224, 225, 
232). One possible method of incorporation is that hepatocytes surrounding dying and damaged 
cholangiocytes convert to replace injured biliary epithelium. If this occurs ducts would become a 
mosaic of hepatocyte-derived and native cholangiocytes (Figure 7A). The other possible method 
of incorporation is in order to expedite the removal of bile from the parenchyma hepatocytes 
transdifferentiate to form de novo ducts. If this occurs whole ducts would be comprised solely of 
hepatocyte-derived cholangiocytes (Figure 7B). Therefore, a study that determines the pattern of 




Figure 7. Hepatocyte-derived cholangiocyte incorporations into bile ducts 
(A) Hepatocytes transdifferentiate into cholangiocytes and incorporate into the injured bile duct to alleviate biliary 
injury creating a bile duct that is a mosaic of native cholangiocytes and hepatocyte-derived cholangiocytes. (B) 
Hepatocytes transdifferentiate into cholangiocytes then form de novo ducts to replace the injured bile duct.  
 
Similarly, the functional capacity of these transdifferentiated cells has yet to be compared 
to native cholangiocytes. It is likely that once these cells have incorporated into ducts, they perform 
most functions of native cholangiocytes. However, they may perform with less efficiency 
depending on the type of selective pressure that initiated the transdifferentiation. If there is 
sufficient selective pressure, such as bile duct paucity, hepatocytes are known to transdifferentiate 
into mature cholangiocytes that form functional bile ducts (232). However, it has also been shown 
under circumstances when injury is reserved reprogrammed cells can revert back to hepatocytes 
(225). This conversion and reversion of hepatocytes is more consistent with metaplasia than it is 
transdifferentiation. Finally, hepatocytes expressing biliary markers may never fully convert into 
a cholangiocyte (233, 234). Instead, these cells exist in a biphenotypic intermediate state. These 
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cells may be able to perform some cholangiocyte functions, such as forming intermediate bile 
channels and bile modification, which helps to prevent injury progression. This biphenotypic cell 
type is also beneficial because these cells are able to evade cholangiocyte-directed immune injury.  
1.4.3 GC-1 as a Potential Driver of Hepatocyte-to-Cholangiocyte Transdifferentiation 
Thyroid hormones, such as triiodothyronine (T3), is a commonly used therapy in patients 
which regulates a wide range of genes and affects many physiological processes in the body, 
including heart rate, metabolism, growth and development, and body temperature (235-237). In 
rodent livers, T3 increases hepatocyte proliferation after partial hepatectomy in a β-catenin 
dependent manner through interaction with thyroid hormone receptor β (TRβ) (29, 30, 238, 239). 
However, T3 is not liver specific as it is also known to have mitogenic effects in other organs such 
as the heart, and pancreas (239, 240). Luckily GC-1, or sobetirome, is a liver specific thyroid 
hormone which recapitulates T3’s β-catenin–dependent hepatocyte proliferation after partial 
hepatectomy (241). 
Unfortunately, GC-1 and other thyroid hormones have not been well studied in the context 
of cholestatic disease. However, GC-1 could be a promising therapeutic for PSC patients. This is 
because GC-1 induces hepatocyte proliferation through a β-catenin activity, which has also been 
implicated as an important signaling pathway during hepatocyte transdifferentiation. During 
cholestatic injury, with the proper selective pressures, GC-1 could be used to induce β-catenin 
dependent hepatocyte-to-cholangiocyte transdifferentiation, since GC-1 is known to activate β-
catenin. Therefore, a study determining the therapeutic effects GC-1 has on biliary injury and 
hepatocyte-to-cholangiocyte transdifferentiation during cholestasis could be a worthwhile 
endeavor.  
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2.0 The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse Model 
of Hepatic Cholestasis 
In this section we characterize the exposure of mice lacking Mdr2 to the thyromimetic 
sobetirome (GC-1) in diet form. We predict that mice lacking Mdr2 will have increased β-catenin 
activity inducing proliferation and hepatocyte-to-cholangiocyte transdifferentiation after GC-1 
exposure, and we will discuss our results and interpretations in detail. This study was published in 
The American Journal of Pathology PMID: 32205094 (242). As first author, the publisher Elsevier 
has granted full permission to reuse the manuscript in this dissertation.   
2.1 Paper Summary 
Chronic cholestasis results from bile secretory defects or impaired bile flow with few 
effective medical therapies available. Thyroid hormone triiodothyronine and synthetic thyroid 
hormone receptor agonists, such as sobetirome (GC-1), are known to impact lipid and bile acid 
(BA) metabolism and induce hepatocyte proliferation downstream of Wnt/β-catenin signaling after 
surgical resection; however, these drugs have yet to be studied as potential therapeutics for 
cholestatic liver disease. Herein, GC-1 was administered to ATP binding cassette subfamily B 
member 4 (Abcb4-/-; Mdr2-/-) knockout (KO) mice, a sclerosing cholangitis model. KO mice fed 
GC-1 diet for 2 and 4 weeks had decreased serum alkaline phosphatase, but increased serum 
transaminases compared with KO alone. KO mice on GC-1 also had higher levels of total liver 
BA due to alterations in expression of BA detoxification, transport, and synthesis genes, with the 
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net result being retention of BA in the hepatocytes. Interestingly, GC-1 does not induce hepatocyte 
proliferation or Wnt/β-catenin signaling in KO mice, likely a result of decreased thyroid hormone 
receptor β expression without Mdr2. Therefore, although GC-1 treatment induces a mild protection 
against biliary injury in the early stages of treatment, it comes at the expense of hepatocyte injury 
and is suboptimal because of lower expression of thyroid hormone receptor β. Thus, thyromimetics 
may have limited therapeutic benefits in treating cholestatic liver disease. 
2.2 Background  
Many chronic liver diseases have few to no medical therapies that are capable of halting or 
reversing disease progression, and the only life-extending treatment is orthotopic liver 
transplantation. Primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease of 
unknown etiology, is one such example. Patients with PSC have bile duct inflammation and 
fibrosis, which results in end-stage liver disease and reduced life expectancy (243, 244). A 
significant number (40%) of PSC patients will ultimately require liver transplant and up to 25% of 
patients who receive liver transplant will have recurrent PSC (151). Therefore, an effective 
therapeutic strategy to treat PSC is a major unmet clinical need.   
ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) gene knockout (KO) 
mice spontaneously develop sclerosing cholangitis characterized by pericholangitis, ductular 
proliferation, and onion skin-type periductal fibrosis (214). This phenotype is due to lack of the 
Mdr2 gene, a canalicular flippase that transports phospholipids into bile (208). The loss of 
protective phospholipids in the KO leads to increased concentrations of free toxic bile acids (BAs), 
which damages cholangiocytes and causes bile to leak into the parenchyma (204). Because the 
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resulting liver injury resembles PSC, these mice have long been used to study the pathogenesis 
and signaling pathways involved in this disease, as well as to test potential therapeutics.  
The Wnt/β-catenin signaling pathway has a well-described role in liver physiology and 
pathology, and its modulation also alters the progression of cholestatic liver disease (245). Loss or 
inhibition of β-catenin (alias catenin β 1) leads to improved outcomes after bile duct ligation and 
5-diethoxycarbonyl-1,4-dihydrocollidine, two commonly used animal models of cholestasis (246, 
247). However, it was recently shown that knockdown of β-catenin in Mdr2 KO leads to increased 
inflammation, oxidative stress, fibrosis, and impaired hepatocyte proliferation (44). In this case, 
β-catenin is essential in maintaining homeostasis in the absence of Mdr2, and its loss results in 
decompensation and increased injury. Thus, in some types of cholestatic conditions, such as those 
modeled by the Mdr2 KO mouse, activation of β-catenin may be advantageous by balancing 
ongoing injury with a robust regenerative response.   
Thyroid hormones, such as triiodothyronine (T3), are known to have mitogenic effects in 
many organs, such as the liver, heart, and pancreas (239, 240). In hepatocytes, T3 increases 
proliferation in mice through interaction with thyroid hormone receptor β (alias TRβ) (238, 239). 
This occurs in a β-catenin–dependent manner via the cAMP-dependent protein kinase A pathway, 
which, in turn, leads to phosphorylation of β-catenin at Ser675 and subsequent activation (29, 30). 
However, because T3 is not liver specific, use of a selective TRβ agonist, such as GC-1 or 
sobetirome, is preferable because of its lack of off-target effects (241). GC-1 is also well studied 
in the liver and has been shown to recapitulate the mitogenic effects of T3, stimulating β-catenin–
dependent hepatocyte proliferation after partial hepatectomy (29). However, whether these drugs 
can induce proliferation and repair during cholestatic liver disease is unknown.   
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In this study, wild-type (WT) and Mdr2 KO mice were treated with a GC-1–containing 
diet to activate β-catenin in hepatocytes. It was hypothesized that activation of β-catenin in this 
model of cholestasis would induce compensatory proliferation that may provide protection against 
injury. The study results show that biliary injury is transiently decreased in Mdr2 KO mice on GC-
1 diet compared with Mdr2 KO mice on normal diet. This decrease in biliary injury is likely due 
to a lack of BA export by the hepatocytes, which spares cholangiocytes but leads to increased 
hepatic injury due to toxic BA retention. Also, although hepatocyte proliferation is increased in 
Mdr2 KO mice, it is not further induced by GC-1, nor is β-catenin activated in KO with GC-1. 
This is because KO have decreased responsiveness to GC-1 because of lesser expression of thyroid 
receptor β. This study shows that dysregulation of receptor targets during chronic liver disease 
may affect drug efficacy, and that caution should be used when considering the use of repurposed 
drugs to treat cholestatic liver diseases. 
2.3 Materials and Methods 
2.3.1 Animal Model 
All animal studies were performed in accordance with the guidelines of the Institutional 
Animal Use and Care Committee at the University of Pittsburgh School of Medicine (Pittsburgh, 
PA) and the NIH (Bethesda, MD; protocol number 17071066). Five-week–old Mdr2 (−/−) KO mice 
in an FVB/NJ background (Jackson Laboratory, Bar Harbor, ME; stock number 002539) or WT 
littermate controls were fed standard mouse chow or GC-1/sobetirome-supplemented diet (5 
mg/kg of diet, GC-1/sobetirome purchased from MedChem Express, Monmouth Junction, NJ; diet 
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from Animal Specialties and Provisions LLC, Quakertown, PA) for up to 4 weeks. After the diet 
course was complete, mice were sacrificed, and blood serum and livers were collected. Livers were 
sectioned, fixed in 10% formalin, and processed for paraffin embedding or frozen in liquid 
nitrogen and stored at −80°C. For baseline, n = 3 mice per genotype. For 1-week GC-1 or normal 
diet, n = 4 WT, n = 3 WT + GC-1, n = 4 KO, and n = 3 KO + GC-1. For 2-week GC-1 or normal 
diet, n = 5 WT, n = 8 WT + GC-1, n = 6 KO, and n = 7 KO + GC-1. For 4-week GC-1 or normal 
diet, n = 8 WT, n = 7 WT + GC-1, n = 9 KO, and n = 8 KO + GC-1. For 12-week GC-1 or normal 
diet, n = 4 WT, n = 3 WT + GC-1, n = 4 KO, and n = 3 KO + GC-1. 
2.3.2 Serum Biochemistry 
At the time of sacrifice, blood was collected and serum was sent to the University of 
Pittsburgh Medical Center Clinical Chemistry laboratory for biochemical analysis of total and 
direct bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase, and alanine transaminase. 
2.3.3 Immunohistochemical Analysis 
Paraffin-embedded liver tissues were divided into sections (4 μm thick). Sections were 
stained with hematoxylin and eosin or Picro-Sirius Red (Abcam, Cambridge, UK). 
Immunohistochemistry on paraffin-embedded sections was performed on mouse livers, as 
described elsewhere (177). Primary antibodies used were anti–sex-determining region Y-box 
transcription factor 9 (Sox9) antibody (1:100; Abcam), anti–cytokeratin 19 (CK19) antibody (31 
μg/mL; TROMA-III-S; Developmental Studies Hybridoma Bank, Iowa City, IA), and proliferating 
cell nuclear antigen antibody (PC10; 1:4000; Santa Cruz Biotechnology, Dallas, TX). Secondary 
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antibodies were goat anti-rabbit, goat anti-rat, and donkey anti-goat (Chemicon, Temecula, CA), 
and were used at 1 to 400, and staining was detected with 3,3′-diaminobenzidine detection systems 
after incubation with the Avidin-Biotin Complex Kit (Vector Laboratories, Burlingame, CA). 
Apoptotic nuclei were detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling staining using the ApopTag Peroxidase kit (Millipore, Temecula, CA) at the 
University of Pittsburgh Department of Pathology's core immunohistochemistry laboratory. 
Images (1280 by 1024 pixels) were taken on an Olympus Provis scope (Olympus America, Center 
Valley, PA) at the Center for Biological Imaging at the University of Pittsburgh. 
 Sirius Red images were quantified using ImageJ Fiji version 2.0.0-rc-68/1.521 (NIH; 
https://imagej.nih.gov/ij) (248). Each image was split into red, green, and blue channels, from 
which the green channel was selected for optimal separation of staining. The staining was isolated 
by using threshold setting 0 for the upper level and 127 for the lower level, and the percentage of 
the stained area to the total image was measured. A total of five images per mouse liver (n = 3 
mice) were quantified for each genotype. 
CK19 images were quantified by splitting the image into red/green/blue channels with 
ImageJ Fiji, and then quantifying the blue channel using a threshold setting 0 for the upper level 
and 63 for the lower level. The percentage of the stained area to the total image was then calculated. 
A total of five images per mouse liver (n = 3 mice) were quantified for each genotype. 
Quantification of proliferating cell nuclear antigen– and terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling–positive cells was performed by counting the 
number of positive hepatocytes per ×100 field. A total of five images per mouse liver (n = 3 mice) 
were quantified for each genotype. 
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2.3.4 Protein Extraction and Western Blot Analysis 
Whole-cell liver lysates were prepared in radioimmunoprecipitation assay buffer 
containing fresh phosphatase and protease inhibitor cocktails (Sigma Aldrich, St. Louis, MO). 
Denatured proteins were separated on 10% SDS-PAGE gels and transferred to polyvinylidene 
difluoride membranes. Membranes were blocked using 5% nonfat dry milk or 5% bovine serum 
albumin in 0.1% Triton X-100 in Tris-buffered saline at room temperature for 1 hour and incubated 
at 4°C overnight with primary antibodies (diluted in 3% blocking media). The following primary 
antibodies were used: glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:5000; Invitrogen, 
Carlsbad, CA), purified mouse anti–β-catenin (1:500; BD Biosciences, San Jose, CA), 
nonphosphorylated (active) β-catenin (Ser33/37/Thr41) (1:1000; Cell Signaling Technology, 
Danvers, MA), and phosphorylated β-catenin (Ser675; D2F1; 1:1000; Cell Signaling Technology). 
Membranes were washed three times for 15 minutes each in Tris-buffered saline before being 
probed with horseradish peroxidase–conjugated secondary antibodies (1:20,000 diluted in 3% 
blocking media; Santa Cruz Biotechnology) for 2 hours at room temperature. Membranes were 
washed three times for 15 minutes each in Tris-buffered saline and visualized using the Enhanced 
Chemiluminescence System (GE Healthcare, Little Chalfont, UK). 
2.3.5 Quantitative Real-Time PCR 
Total RNA was isolated from frozen liver tissue using Trizol reagent (Invitrogen). RT-
PCR was performed as described elsewhere (177). Real-time PCR was performed on a CFX96 
TouchReal-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA) using SYBR 
Green (Thermo Fisher Scientific, Pittsburgh, PA). Changes in target mRNA were normalized to 
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GAPDH mRNA for each sample, and P value is presented as fold change over the average from 
three normal livers. Three samples per each condition were assayed in triplicate. Primer sequences 
are provided in Table 1. 
Table 1. List of Primers Used for Quantitative RT-PCR Analysis in Section 2.0 
BSEP, bile salt export pump; CAR, constitutive androstane receptor; CK19, cytokeratin 19; Cyp, cytochrome P450; 
FXR, farnesoid X receptor; HNF1β, hepatocyte nuclear factor 1 homeobox B; NTCP, sodium-taurocholate 
cotransporting polypeptide; PXR, pregnane X receptor; SHP, small heterodimer partner; Slco1b2, solute carrier 
organic anion transporter family, member 1b2; MRP, multidrug resistance protein; Sox9, sex-determining region Y-
box transcription factor 9; TRβ, thyroid hormone receptor β. 
Primer name Sequence 
PXR (forward) 5′-CCCATCAACGTAGAGGAGGA-3′ 
PXR (reverse) 5′-GGGGGTTGGTAGTTCCAGAT-3′ 
SHP (forward) 5′-TCTGCAGGTCGTCCGACTATTC-3′ 
SHP (reverse) 5′-AGGCAGTGGCTGTGAGATGC-3′ 
FXR (forward) 5′-CTTGATGTGCTACAAAAGCTGTG-3′ 
FXR (reverse) 5′-ACTCTCCAAGACATCAGCATCTC-3′ 
CAR (forward) 5′-GGAGGACCAGATCTCCCTTC-3′ 
CAR (reverse) 5′-ATTTCATTGCCACTCCCAAG-3′ 
NTCP (forward) 5′-CACCATGGAGTTCAGCAAGA-3′ 
NTCP (reverse) 5′-AGCACTGAGGGGCATGATAC-3′ 
Slco1b2 (forward) 5′-GATCCTTCACTTACCTGTTCAA-3′ 
Slco1b2 (reverse) 5′-CCTAAAAACATTCCACTTGCCATA-3′ 
MRP2 (forward) 5′-GCTTCCCATGGTGATCTCTT-3′ 
MRP2 (reverse) 5′-ATCATCGCTTCCCAGGTACT-3′ 
MRP3 (forward) 5′-TGAGATCGTCATTGATGGGC-3′ 
MRP3 (reverse) 5′-AGCTGCGAGCGCAGGTCG-3′ 
MRP4 (forward) 5′-TTAGATGGGCCTCTGGTTCT-3′ 
MRP4 (reverse) 5′-GCCCACAATTCCAACCTTT-3′ 
BSEP (forward) 5′-ACACCATTGTATGGATCAACAGC-3′ 
BSEP (reverse) 5′-CACCAACTCCTGCGTAGATGC-3′ 
Cyp7a1 (forward) 5′-TGGGCATCTCAAGCAAACAC-3′ 
Cyp7a1 (reverse) 5′-TCATTGCTTCAGGGCTCCTG-3′ 
Cyp3a11 (forward) 5′-CCACCAGTAGCACACTTTCC-3′ 
Cyp8b1 (forward) 5′-GCCCTTACTCCAAATCCTACCA-3′ 
Cyp8b1 (reverse) 5′-TCGCACACATGGCTCGAT-3′ 
Cyp27 (forward) 5′-TGCCTGGGTCGGAGGAT-3′ 
Cyp27 (reverse) 5′-GAGCCAGGGCAATCTCATACTT-3′ 
Cyp3a11 (reverse) 5′-TTCCATCTCCATCACAGTATCA-3′ 
Cyp2B10 (forward) 5′-CAATGGGGAACGTTGGAAGA-3′ 
Cyp2B10 (reverse) 5′-TGATGCACTGGAAGAGGAAC-3′ 
CK19 (forward) 5′-GACCTGGAGATGCAGATTGAG-3′ 
CK19 (reverse) 5′-GCTCCTCAGGGCAGTAATTT-3′ 
Sox9 (forward) 5′-CAGGCAAGAATTGGGCAAAG-3′ 
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Table 1 continued 
Sox9 (reverse) 5′-CCTCCCAACACGCAGTAAA-3′ 
HNF1β (forward) 5′-AACCAGCCGGGAAACAATGA-3′ 
HNF1β (reverse) 5′-CTCCCGACACTGTGATCTGC-3′ 
TRβ1 (forward) 5′-GGACAAGCACCCATCGTGAAT-3′ 
TRβ1 (reverse) 5′-CTCTGGTAATTGCTGGTGTGAT-3′ 
TRβ2 (forward) 5′-CCAGAGGTACACGAAGTGTGC-3′ 
TRβ2 (reverse) 5′-AGGTTTCCAGGGTAACTACAGG-3′ 
 
2.3.6 Measurement of Bile Acids 
Total BAs (n = 3 samples per condition) were isolated from frozen liver using 70% ethanol, 
as previously described (247). Bile was also extracted from gallbladders and diluted 1:5 in distilled 
water. The Mouse Total Bile Acids Assay Kit (Crystal Chem, Downers Grove, IL) was used to 
measure BAs in both liver and bile, and the calibration curve and mean change in absorbance value 
for each sample were used to determine the concentration of each sample. 
2.3.7 Statistical Analysis 
Data are presented as means, SD, and/or individual data points. Data were analyzed, and 
graphs were generated using Prism GraphPad 7.0c (GraphPad Software, San Diego, CA). P values 
were determined using the two-tailed t-test, one-way analysis of variance followed by an 
appropriate post hoc test, or two-way analysis of variance followed by the appropriate post hoc 
test. P < 0.05 was considered statistically significant. 
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2.4 Results 
2.4.1 Biliary Injury Is Decreased in KO after Short-Term GC-1 Diet 
WT and KO mice were fed normal diet or GC-1 supplemented diet for 1, 2, 4, and 12 weeks 
and assessed for serum biochemical markers of liver injury. GC-1 diet did not affect total serum 
bilirubin levels nor liver weight/body weight ratios in KO mice, although conjugated bilirubin 
levels were decreased at 12 weeks (Figure 8). Surprisingly, hepatic injury, as assessed by 
measurement of serum transaminases aspartate aminotransferase and alanine transaminase, was 
significantly increased in KO fed GC-1 as early as 2 weeks after the start of diet, although these 
numbers tended to normalize or decrease at 12 weeks (Figure 9A). Terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling staining also revealed increased hepatocyte death in 
KO + GC-1 treated livers at 2 and 4 weeks of diet (Figure 10). On the contrary, biliary injury in 
KO mice on GC-1 diet was significantly decreased compared with KO mice on normal diet at both 
2 and 4 weeks, as shown by a reduction in serum ALP, but was comparable in KO with and without 
diet at 12 weeks. To investigate parenchymal injury, hematoxylin and eosin stains of liver sections 
were performed. KO mice fed GC-1 diet show equivalent portal damage, including inflammation 
and ductular reaction, as early as 2 weeks compared with KO mice on normal diet, with this trend 
following into 4 weeks as well (Figure 9B). Thus, despite a transient decrease in biliary injury, KO 




Figure 8. GC-1 does not affect serum bilirubin or the liver weight/body weight (LW/BW) ratio of ATP 
binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice 
Blood serum levels of conjugated bilirubin and total bilirubin, as well as LW/BW ratio, are significantly increased in 
KO mice compared with wild-type (WT) mice, but GC-1 has no effect on these parameters at most time points, 
although conjugated bilirubin levels were decreased at 12 weeks in KO + GC-1 compared with KO alone. n ≥ 3 mice 
per group. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗∗P < 0.0001 versus KO at all time points. 
 
 
Figure 9. Biliary injury improves in ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) 
knockout (KO) mice at 2 and 4 weeks after GC-1, at the expense of hepatic injury 
(A) Blood serum levels of alkaline phosphatase (ALP) show decreased biliary injury, whereas alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) indicate increased hepatic injury, in KO mice on short-
term GC-1 diet compared with KO mice. (B) Representative hematoxylin and eosin images show equivalent 
parenchymal injury in KO mice on GC-1 diet for 2 and 4 weeks compared with KO mice on normal diet. n ≥ 3 mice 
per group (A). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 wild type (WT) versus WT GC-1; ††P < 0.01, †††P < 0.001 





Figure 10. GC-1 treatment induces hepatocyte death in vivo 
(A) Representative terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) images show 
that there is more cell death in ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) 
mice on GC-1 at both time points compared with KO mice. (B) TUNEL quantification shows increased hepatocyte 
death in KO mice treated with GC-1 compared with KO mice after 2 and 4 weeks of GC-1 exposure. ∗P < 0.05, ∗∗P 
< 0.01 versus KO GC-1; ††P < 0.01 versus KO GC-1; ‡P < 0.05 versus KO. Original magnification, ×50 (A). 
2.4.2 Fibrosis and Ductular Response Are Equivalent in KO Mice Fed GC-1 
To determine if lower ALP levels in KO with GC-1 at 2 and 4 weeks correlate with 
decreased ductular mass and portal fibrosis, the fibrotic content of these livers was assessed by 
Sirius Red staining and quantification. KO mice on GC-1 diet have significantly less porto-portal 
bridging fibrosis after 2 weeks of diet exposure compared with KO mice, and a trend toward 
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decreased fibrosis at 4 weeks (Figure 11, A and C). Quantitative PCR analysis of biliary markers 
Sox9, cytokeratin 19 (official name Krt19), and hepatocyte nuclear factor 1 homeobox B (official 
name Hnf1b) shows that expression of common cholangiocyte markers is also decreased in KO 
mice on GC-1 compared with KO mice alone at both 2 and 4 weeks (Figure 11E). 
Immunohistochemistry for Sox9, however, indicates that the reduction in biliary markers may be 
due to notably fewer hepatocytes expressing biliary markers after GC-1 compared with KO mice 
on normal diet (Figure 12), rather than a reduction in the number of biliary structures. To directly 
assess biliary mass in KO after GC-1, immunohistochemistry and quantification of CK19, a marker 
of fully differentiated cholangiocytes, were performed. No significant differences in the amount 
of CK19 positivity between KO with or without GC-1 at either 2 or 4 weeks was observed (Figure 
11, B and D). It is concluded that although fibrosis is transiently decreased in KO after 2 weeks of 
diet, on the whole, neither fibrosis nor ductular response is significantly changed over time in 




Figure 11. ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice treated with 
GC-1 have decreased liver fibrosis but similar ductular response compared with KO mice on normal diet 
(A) and (B) Representative Sirius Red (A) and cytokeratin 19 (CK19; B) images. (C) Quantification of Sirius Red 
stain shows less fibrosis in KO mice of GC-1 diet compared with KO mice after 2 weeks on diet. (D) Quantification 
of CK19 shows that KO mice both on and off GC-1 diet have increased ductular response compared with wild-type 
(WT) mice after 2 and 4 weeks. (E) Quantitative RT-PCR analysis of cholangiocyte markers sex-determining region 
Y-box transcription factor 9 (Sox9), CK19, and hepatocyte nuclear factor 1 homeobox B (HNF1β) in WT mice, WT 
mice fed GC-1 diet, KO mice, and KO mice fed GC-1 diet for 2 and 4 weeks shows decreased expression of these 
markers in KO treated with GC-1. n = 3 mice per group (E). ∗∗∗∗P < 0.0001 WT versus WT GC-1; †P < 0.05, ††††P 
< 0.0001 KO versus KO GC-1; ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001, and ‡‡‡‡P < 0.0001 WT versus KO; §P < 0.05, 




Figure 12. Sex-determining region Y-box transcription factor 9 (Sox9) immunohistochemistry shows that 
ATP binding cassette subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice and KO mice treated 
with GC-1 have increased ductular reaction compared with both untreated wild-type (WT) mice and WT 
mice treated with GC-1 at 2 and 4 weeks 
Representative Sox9 images show increased ductular response in KO mice both on and off GC-1 treatment compared 
with WT mice, after 2 and 4 weeks. Also notable is the increased number of Sox9-positive hepatocytes in KO on 
normal diet compared with KO + GC-1 diet. Original magnification, ×200. 
2.4.3 GC-1 Alters the Amount and Location of BAs in Mdr2 KO Mice through Differential 
Regulation of Hepatic BA Transporters and Synthesis Enzymes 
Despite insignificant differences during the 12-week time point, this study intended to 
further characterize the phenotype of KO mice at the early stage of GC-1 treatment. Because 
hepatic injury increases simultaneously with decreased biliary injury in KO fed GC-1, it is 
hypothesized that alterations in BA synthesis, detoxification, or transport may be responsible.  
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Measurement of BAs shows that KO mice on GC-1 for 2 weeks have higher total hepatic 
BAs compared with both KO on normal diet and WT mice on GC-1 (Figure 13A). However, at 4 
weeks, KO mice with and without GC-1 have similar levels of hepatic BAs, which are both 
elevated compared with WT mice (Figure 13A). At 4 weeks, a trend was also noted toward 
decrease in BA excretion, as KO fed GC-1 for 4 weeks have decreased biliary (gallbladder) BA 
levels compared with KO alone (Figure 13B). Thus, by 4 weeks, KO have compensated for 
increased BA accumulation after GC-1 by altering the amount and location of BA in the liver. 
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Figure 13. Bile acid excretion is dysregulated in ATP binding cassette subfamily B member 4 (Abcb4−/−; 
Mdr2−/−) knockout (KO) mice on GC-1 diet, concomitant with altered nuclear receptor and cytochrome P450 
(Cyp) gene expression 
(A) Total hepatic bile acids are increased in KO mice on GC-1 diet after 2 weeks compared with KO controls, but 
after 4 weeks, bile acid retention in the liver of KO on GC-1 is similar to KO on normal diet. (B) Measurement of bile 
acids collected from the gallbladder shows a trend toward decreased bile excretion in KO after 4 weeks of GC-1. (C) 
Quantitative RT-PCR analysis of farnesoid X receptor (FXR), small heterodimer partner (SHP), pregnane X receptor 
(PXR), and constitutive androstane receptor (CAR) shows that, after GC-1 diet, both wild-type (WT) and KO mice 
have decreased FXR, whereas after 4 weeks of diet, KO mice have increased PXR and decreased SHP; CAR is 
decreased generally in KO with and without diet. (D) Bile acid synthesis gene Cyp family 7 subfamily A member 1 
(Cyp7a1) is increased in KO + GC-1 at 2 weeks, but repressed in KO after 4 weeks of GC-1 treatment, whereas Cyp 
family 8 subfamily B member 1 (Cyp8B1) and Cyp family 27 (Cyp27) are decreased in KO irrespective of GC-1 
treatment. Detoxification genes Cyp family 3 subfamily a polypeptide 11 (Cyp3a11) and Cyp family 2 subfamily b 
polypeptide 10 (Cyp2b10) decreased in both WT and KO after 4 weeks of GC-1. n = 3 mice per group (A–D). ∗P < 
0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 WT versus WT GC-1; †P < 0.05, ††P < 0.01, †††P < 0.001, and ††††P < 0.0001 
KO versus KO GC-1; ‡P < 0.05, ‡‡P < 0.01, and ‡‡‡P < 0.001 WT versus KO; §P < 0.05, §§P < 0.01, and §§§§P < 
0.0001 WT GC-1 versus KO GC-1. 
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Quantitative PCR analysis was then used to determine if nuclear receptors associated with 
BA synthesis—farnesoid X receptor [FXR; alias nuclear receptor subfamily 1 group H member 4 
(Nr1h4)], small heterodimer partner [alias nuclear receptor subfamily 0 group B member 2 
(Nr0b2)], pregnane X receptor [alias nuclear receptor subfamily 1 group I member 2 (Nr1i2)], and 
constitutive androstane receptor [alias coxsackie virus and adenovirus receptor Ig-like cell 
adhesion molecule (Cxadr)]—were altered after GC-1 exposure. FXR and its downstream target 
small heterodimer partner are master regulators of BA synthesis, whereas pregnane X receptor and 
constitutive androstane receptor regulate expression of cytochrome P450 (Cyp) genes involved in 
detoxifying and transporting BAs (249, 250). This study found that GC-1 reduced expression of 
FXR after 2 and 4 weeks of treatment, a finding that was consistent across both genotypes (Figure 
13C). On the other hand, only KO show a decrease in small heterodimer partner after 4 weeks of 
GC-1 exposure, despite similar expression levels to WT at 2 weeks. Interestingly, expression of 
pregnane X receptor is dramatically increased in KO after 4 weeks of GC-1 diet, whereas 
constitutive androstane receptor expression is suppressed in KO generally, and GC-1 decreases 
expression further at 4 weeks (Figure 13C). Thus, the disparate regulation of some nuclear 
receptors, with the exception of FXR, indicates a compensatory response to GC-1 that is exclusive 
to KO. 
To determine the impact on BA synthesis and detoxification, the expression of the Cyps 
involved in these processes was next analyzed. Interestingly, Cyp7a1, the rate-limiting enzyme 
involved in BA synthesis from cholesterol, is induced in KO mice on GC-1 for 2 weeks compared 
with KO mice, but significantly suppressed after 4 weeks of GC-1 exposure; expression in WT is 
unchanged at either time point after GC-1 (Figure 13D). Cyp8b1, which is downstream of Cyp7a1 
and synthesizes cholic acid, is suppressed in the KO mice regardless of GC-1 treatment. Likewise, 
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Cyp27, which initiates the alternative BA synthesis pathway, is decreased in KO at both 2 and 4 
weeks. Finally, expression of Cyp3a11 and Cyp2b10, which are involved in BA detoxification, 
significantly decreases after GC-1 diet in both WT and KO mice (Figure 13C). The results show 
that alternations in BA synthesis and detoxification occur early after GC-1 treatment and may 
subsequently affect both BA levels and toxicity. 
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Figure 14. Bile acid transporter genes are altered after GC-1 diet, which leads to toxic bile retention in 
hepatocytes 
(A) Quantitative RT-PCR analysis of uptake transporters sodium/taurocholate cotransporting polypeptide (NTCP) and 
solute carrier organic anion transporter family, member 1b2 (Slco1b2), shows decreased expression in wild-type (WT) 
and knockout (KO) after 4 weeks of GC-1 diet, although both are suppressed in KO on normal diet as well. (B) Efflux 
transporter ATP binding cassette subfamily C member 2 gene [Abcc2; alias multidrug resistance protein 2 (MRP2)] 
is decreased at 4 weeks in both WT and KO on GC-1 compared with controls, whereas bile salt export pump (BSEP) 
is unchanged. (C) ATP binding cassette subfamily C member 3 (Abcc3; alias MRP3) is significantly repressed in both 
WT and KO on GC-1 at 2 and 4 weeks, whereas ATP binding cassette subfamily C member 4 (Abcc4; alias MRP4) 
is unchanged. n = 3 mice per group (A–C). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 versus WT GC-1; ††P < 0.01, 
†††P < 0.001 versus KO GC-1; ‡‡P < 0.01, ‡‡‡P < 0.001, and ‡‡‡‡P < 0.0001 versus KO; §P < 0.05, §§§P < 0.001 
GC-1 versus KO GC-1. 
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Finally, the expression of genes involved in BA transport to identify any dysregulation in 
the presence of GC-1 was analyzed. Bile acid uptake transporters sodium-taurocholate 
cotransporting polypeptide [alias solute carrier family 10 member 1 (Slc10a1)] and solute carrier 
organic anion transporter family, member 1b2 [Slco1b2; (Slo)1b2], which are already decreased 
in KO mice compared with WT, are further reduced in both WT and KO after 4 weeks of GC-1 
(Figure 14A). Expression of apical BA efflux transporter, ATP binding cassette subfamily C 
member 2 [Abcc2; alias multidrug resistance protein 2 (MRP2)], is decreased in both WT and KO, 
albeit only after 4 weeks of GC-1, whereas the bile salt export pump, another efflux transporter, is 
unchanged between WT and KO with or without GC-1 at either time point (Figure 14B). Decreased 
expression of MRP3, a basolateral BA efflux transporter, officially known as ATP binding cassette 
subfamily C member 3 (Abcc3), is also seen in both WT and KO at 2 and 4 weeks, indicating a 
direct repression by GC-1, whereas MRP4, another basolateral transporter officially known as 
ATP binding cassette subfamily C member 4 (Abcc4), is unchanged (Figure 14C). Overall, GC-1 
induces down-regulation of FXR, BA uptake and efflux transporters, and detoxification enzymes 
in both WT and KO, with net result being that hepatocytes retain more toxic BAs compared with 
hepatocytes from mice on normal diet (Figure 15). However, KO mice on GC-1 also show 
increased Cyp7a1 expression at 2 weeks, which may account for the elevated levels of BAs and 
increased hepatic damage at this time point. 
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Figure 15. Schematic of changes in bile acid transporters and detoxification enzymes in ATP binding cassette 
subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice on GC-1 after 2 and 4 weeks of diet 
exposure compared with mice on normal diet 
(A) Uptake transporter genes sodium-taurocholate cotransporting polypeptide [NTCP; alias solute carrier family 10 
member 1 (Slc10a1)] and solute carrier organic anion transporter family, member 1b2 (Slco1b2), and efflux transporter 
[ATP binding cassette subfamily C member 2 gene (Abcc2); alias Mrp2] are equivalent in KO mice after 2 weeks of 
GC-1 diet, whereas Mrp3 [alias ATP binding cassette subfamily C member 3 (Abcc3)] is suppressed and cytochrome 
P450 (Cyp) 7a1 is increased, indicating that hepatocytes are starting to retain bile acids after 2 weeks of GC-1 diet 
exposure. (B) After 4 weeks of diet, uptake, efflux, synthesis, and detoxification, genes are all decreased, indicating 
hepatocytes are no longer capable of detoxifying or exporting bile acids. 
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2.4.4 GC-1 Neither Induces Hepatocyte Proliferation nor Inhibits Cholangiocyte 
Proliferation in Mdr2 KO Mice 
Hepatocyte proliferation is an important component of the reparative response in chronic 
liver injury, and is often deficient in patients with cholestasis (251-254). As GC-1 has been shown 
to have mitogenic effects on hepatocytes, specifically after partial hepatectomy, the cell 
proliferation in our model was analyzed (29). Quantification of proliferating cell nuclear antigen 
immunohistochemistry shows increased hepatocyte proliferation in WT mice administered GC-1, 
as expected (Figure 16). However, hepatocyte proliferation in Mdr2 KO mice on normal diet, 
which was significantly elevated compared with WT, was not further induced by GC-1. A previous 
study has also found that thyroid hormone inhibits biliary growth both in vitro and in vivo, 
suggesting a cell autonomous role of thyroid receptor activation in cholangiocyte proliferation 
(255). However, neither WT nor KO mice exposed to GC-1 diet had any significant changes in 
cholangiocyte proliferation compared with mice fed normal diet (Figure 16). Thus, GC-1 diet does 
not affect proliferation of cholangiocytes, and hepatocyte proliferation is increased in WT but not 
Mdr2 KO after GC-1. 
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Figure 16. GC-1 has no effect on either hepatocyte or cholangiocyte proliferation in ATP binding cassette 
subfamily B member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) mice 
(A) Representative proliferating cell nuclear antigen (PCNA) images. (B) PCNA quantification shows that hepatocyte 
proliferation increases after GC-1 in wild type (WT) and increases significantly between WT and KO, but not between 
KO and KO + GC-1. Cholangiocyte proliferation in livers of KO mice fed GC-1 diet is also comparable to mice fed 
normal diet. ∗∗P < 0.01 versus WT GC-1; †P < 0.05 versus KO GC-1. Original magnification, ×200 (A). 
2.4.5 GC-1 Does Not Activate β-Catenin in Mdr2 KO Mice 
As the effect of GC-1 on hepatocyte proliferation is β-catenin dependent, a Western blot 
analysis of key phosphorylation sites that regulate β-catenin activation was performed. Previous 
studies have shown that GC-1 increases phosphorylation of β-catenin at serine 675 (S675) (29). 
However, KO mice fed GC-1 diet have decreased S675 phosphorylated β-catenin after 2 and 4 
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weeks of diet exposure compared with KO mice on normal diet (Figure 17). This decrease in S675 
phosphorylated β-catenin indicates that the changes seen in the KO mice on GC-1 compared with 
the KO mice are not driven by protein kinase A–dependent β-catenin activation. To determine if 
GC-1 induces activation of β-catenin through canonical Wnt signaling, an antibody against the 
hypophosphorylated (nonphosphorylated) form of β-catenin was used. No significant changes in 
Wnt-dependent β-catenin activation were observed in KO treated with GC-1 at either the 2- or 4-
week time point, although β-catenin activation was increased in KO livers compared with WT, as 
shown previously (44). 
 
 
Figure 17. β-Catenin is not activated by GC-1 in ATP binding cassette subfamily B member 4 (Abcb4−/−; 
Mdr2−/−) knockout (KO) mice 
Western blot analyses (A) and densitometry of the Western blot analyses (B) for phosphorylated (S675), 
nonphosphorylated active, and total β-catenin shows that KO mice given GC-1 have decreased activation of 
phosphorylated (S675) β-catenin compared with KO mice. ∗P < 0.05 versus WT GC-1; †P < 0.05, ††P < 0.01 versus 
KO GC-1; ‡P < 0.05 versus KO; §P < 0.05, §§P < 0.01, and §§§P < 0.001 versus KO GC-1. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; phospho, phosphorylated; WT, wild-type. 
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2.4.6 TRβ Expression Is Decreased in Mdr2 KO, Resulting in a Blunted Response to GC-1 
The lack of β-catenin activation led us to question whether GC-1 was being efficiently 
taken up and metabolized by the liver. This study sought to verify the effectiveness of GC-1 by 
examining expression of deiodinase, which is a TRβ target gene. Interestingly, although deiodinase 
is significantly up-regulated in WT, particularly at 4 weeks (approximately 30-fold over control), 
expression is increased only approximately 10-fold in KO after 4 weeks (Figure 18A). The study 
then analyzed the expression of the two TRβ isoforms in both WT and KO, and found that both 
were decreased in KO compared with WT at baseline (Figure 18B). Thus, GC-1 may be less 
effective in inducing β-catenin activation and hepatocyte proliferation in KO because of down-
regulation of the receptors that interact with this thyroid hormone analog. 
 
 
Figure 18. GC-1 induces deiodinase expression to a lesser extent in ATP binding cassette subfamily B 
member 4 (Abcb4−/−; Mdr2−/−) knockout (KO) livers than in wild-type (WT) livers, due to decreased 
expression of thyroid hormone receptor β (TRβ) receptor 
(A) Quantitative RT-PCR analysis of deiodinase expression shows that KO have decreased induction after 2 and 4 
weeks of GC-1 diet compared with WT mice (P < 0.01). (B) Expression of the two common isoforms of TRβ is 
decreased in baseline KO mice compared with baseline WT mice. n ≥ 3 mice per group (A). ∗∗P < 0.01 versus WT 
GC-1; ††P < 0.01, †††P < 0.001 versus KO GC-1; ‡P < 0.05, ‡‡P < 0.01 versus KO. 
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2.5 Discussion 
There is some evidence that activation of the Wnt/β-catenin signaling pathway may be 
protective in a subset of patients with cholestatic liver disease. Transgenic mice expressing a 
mutated, nondegradable form of β-catenin had decreased ALP, which is commonly used to monitor 
response to treatment in PSC patients, after long-term treatment with 5-diethoxycarbonyl-1,4-
dihydrocollidine (180). Mdr2 KO mice also required β-catenin activation for maintenance of 
homeostasis (44). Because TRβ agonist was shown to activate β-catenin, it is hypothesized that 
administration of GC-1 might alleviate injury in the Mdr2 KO mouse. However, only a modest 
decrease in biliary injury and fibrosis in KO mice given GC-1, which was restricted to early (2- 
and 4-week) time points, was observed. The improvement in injury was not due to increased 
hepatocyte proliferation and repair, but rather a decrease in the amount of toxic bile entering the 
biliary tree. 
Despite decreased biliary injury, KO showed a significant increase in hepatic injury, as 
assessed by serum aspartate aminotransferase and alanine transaminase, as well as apoptosis. 
Notably, serum ALP, aspartate aminotransferase, and alanine transaminase levels also increased 
in WT mice treated with GC-1. Interestingly, patients with familial hypercholesterolemia taking 
another thyroid hormone mimetic, KB2115, also showed a dose-dependent increase in 
transaminases and conjugated bilirubin (256). It is unknown whether these effects were off target 
or due to the effect of mimicking thyrotoxicosis in the liver; nonetheless, they are consistent with 
previous findings and led to discontinuation of treatment in some cases (256). 
The pathogenesis of injury in Mdr2 KO is complex and multifactorial; however, increased 
concentration of free toxic BAs in the biliary tree is one major contributor. One strategy to reduce 
bile toxicity is to decrease BA output, which can be accomplished by treating these mice with the 
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dual FXR and G-protein–coupled membrane BA receptor (TGR5) agonist INT767 (257). In this 
study, GC-1 treatment of KO led to higher BA levels in the liver but lower levels in gallbladder 
bile than WT or KO on normal diet, resulting in less biliary injury. It appears that GC-1 causes 
retention of BAs in hepatocytes, thus sparing cholangiocytes from injury (Figure 18A). Indeed, 
GC-1 has important roles in lipid metabolism, including promoting conversion of cholesterol into 
BAs and regulating secretion of cholesterol into bile (258, 259). 
It was intriguing to note that GC-1 enhanced BA toxicity and decreased their export. 
Increased toxicity occurs because of down-regulation of Cyp2b10 (and eventually Cyp3a11). The 
increase in Cyp7a1 in KO on GC-1 at 2 weeks, despite simultaneous decreases in Cyp8b1 and 
Cyp27, likely leads to additional BA accumulation and increased total hepatic BA levels in these 
mice. Alternative export of BAs from the basolateral membrane is suppressed at both 2 and 4 
weeks of diet in both WT and KO by GC-1, as is export from the apical side at 4 weeks. The 
downregulation of BA uptake transporters from the blood is likely a secondary effect of the 
increasing levels of hepatic BAs, particularly in the KO. We believe that, although collectively 
these changes due to GC-1 result in increased biliary injury in WT due to the increased toxicity of 
bile, they induce hepatic injury in KO, because the toxic BAs are accumulating in hepatocytes 
rather than being dumped into bile. Future studies will address if some of these effects of GC-1 
are indirect because of impact on cholesterol metabolism (260). 
GC-1 led to an unexpected decrease in β-catenin expression and activity in Mdr2 KO. A 
previous study had shown GC-1 to activate both Wnt-dependent and Wnt-independent (protein 
kinase A–mediated Ser675 phosphorylation) activation of β-catenin (29). However, both the mode 
of GC-1 delivery and the length of treatment differed between the two studies, which may explain 
the conflicting results. The liver regeneration studies used mice injected with GC-1 for up to 8 
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days and harvested 1 hour after the final injection, which would allow for accurate measurement 
of transient events, such as protein phosphorylation. Conversely, in this study, mice consumed 
GC-1–containing diet ad libitum for a much longer time period (2 and 4 weeks), and were 
sacrificed without fasting. These conditions may not have been optimal for assessing 
phosphorylation events, as these are highly temporal within a cell. 
Furthermore, TRβ expression was suboptimal in KO. It is possible that chronic liver injury 
may induce hepatocyte dedifferentiation, and decreased TRβ expression occurs as a result of this 
reprogramming. Thus, although compensatory hepatocyte proliferation in the Mdr2 KO likely 
occurs as a response to tissue damage, and may provide some protection against chronic injury, 
these cells are less responsive to therapies, such as thyromimetics, which rely on the presence of 
receptors expressed in fully differentiated hepatocytes (261). Further studies are needed to 
investigate the efficacy of thyromimetics in cholestatic models like Mdr2 KO after forced 
expression of TRβ. 
Interestingly, a recent article demonstrated TRβ agonists to increase Mdr2 expression 
transcriptionally (262). This promoted phosphatidylcholine secretion into the bile, increasing bile 
flow and biliary BA output. It is unclear whether this is a reciprocal relationship, with down-
regulation of Mdr2 leading to decreased TRβ, but these results suggest that this may be the case. 
Nonetheless, although the effect on Mdr2 induction was not tested in mouse models of cholestasis, 
in vitro studies using T3 and an FXR agonist showed that the effects of combination therapy are 
additive, resulting in stimulation of Mdr2 expression and sustained repression of Cyp7a1(262). 
This study demonstrates that reducing exposure of the biliary system to toxic BAs has an overall 
beneficial effect, and that the combination of TRβ agonists with other therapeutic modalities, such 
as FXR agonists, may be synergistic in reducing accumulation of BAs in hepatocytes and 
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subsequent hepatic injury. More optimization of TRβ expression would be necessary to test this 
hypothesis, but because thyromimetics are already undergoing preclinical and clinical trials, these 
findings have important implications for drug repurposing and personalized medicine. 
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3.0 Determining the Effects of Wnt Signaling in the Alleviation of Cholestasis Via the 
Promotion of Hepatocyte Transdifferentiation 
In this section we characterize the effects β-catenin signaling has on hepatocyte 
transdifferentiation in mice exposed to 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. We 
predict that mice expressing a transgenic, constitutively active, non-degradable from of β-catenin 
will have increased hepatocyte-to-cholangiocyte transdifferentiation after DDC diet exposure 
compared to control mice exposed to DDC diet. We will discuss our results and interpretations in 
detail.  
3.1 Paper Summary 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease characterized by bile 
duct inflammation and fibrosis, resulting in end-stage liver disease and reduced life expectancy, 
and an effective treatment that does not rely on liver transplant is needed. Hepatocytes exhibit 
remarkable plasticity and are known to be capable of transdifferentiating into cholangiocytes in 
models of biliary injury. These newly derived cholangiocytes could create de novo ducts, repair 
damaged cholangiocytes, or contribute to bile detoxification. Previous studies utilizing in vitro 
organoid cultures and genetic mouse models found that β-catenin and downstream targets are 
upregulated in hepatic organoid cultures, and mice expressing excess β-catenin in the liver had an 
increased number of hepatocytes expressing cholangiocyte markers compared to wild type (WT) 
when subjected to cholestatic injury. These findings led to the hypothesis that Wnt/β-catenin 
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signaling drives hepatocyte-to-cholangiocyte transdifferentiation during biliary injury. To test this 
hypothesis, we utilized lineage tracing in hepatic organoid cultures and TG mice expressing a 
mutated non-degradable form of β-catenin (S45D) in liver. We show that hepatocytes 
transdifferentiate to cholangiocytes in organoid cultures, and the cholangiocytes present are not 
from native contaminating cholangiocytes. We also determined that TG mice fed 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet, which induces bile stasis, have improved 
serum ALP over time, indicating less biliary injury and bile ducts populated with hepatocyte-
derived cholangiocytes. Through these studies we demonstrate that Wnt/β-catenin signaling 
catalyzes hepatocyte-to-cholangiocyte transdifferentiation, and activation of this pathway 
alleviates cholestasis in mouse models of PSC. 
3.2 Background 
As previously stated, primary sclerosing cholangitis (PSC), along with other intrahepatic 
cholestatic liver diseases, can cause serious irreparable damage to bile ducts resulting in end stage 
liver disease that also reduces life expectancy. Currently the only “treatment” for PSC is a liver 
transplant, and that is only if the patients are eligible to receive a donor organ (153, 156). 
Unfortunately, patients have a potential of disease recurrence after transplant (155, 157-160); thus, 
a treatment for PSC that is not reliant on liver transplant is an unmet clinical need. 
Interestingly, a previous study found mice transgenic for a non-degradable S45D-mutated 
β-catenin in the liver (S45D) exposed to 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet 
long-term started to show improved biliary injury markers in their serum and had an increased 
number of hepatocytes positive for A6, a biliary marker, compared to WT mice on DDC diet (180). 
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This study along with data showing that Wnt7A, a known canonical Wnt ligand, induces 
hepatocytes to express biliary markers (69), led us to believe that the alleviation of cholestatic 
disease seen in the S45D mice after long-term DDC exposure is likely due to hepatocyte 
transdifferentiating into cholangiocytes and repairing injured ducts.  
Therefore, we developed the hypothesis that β-catenin signaling will induce hepatocyte-to-
cholangiocyte transdifferentiation alleviating cholestatic injury. To test this hypothesis, we bred 
S45D mice with R26-stopflox/flox-EYFP which allowed us to lineage trace the origin of 
cholangiocytes in bile ducts after biliary injury. We used these mice for both an in vitro organoid 
study and an in vivo study, in which these mice were exposed to DDC diet for up to 6 months and 
monitored hepatocyte transdifferentiation as time progressed. We found that cholangiocytes 
present in organoid cultures are not from native contaminating cholangiocytes, instead they are 
hepatocyte-derived cholangiocytes. We determined that S45D mice fed DDC diet have improved 
serum ALP over time and have bile ducts populated with hepatocyte-derived cholangiocytes, 
which results in alleviated biliary injury over time. Through these studies we demonstrate that β-
catenin signaling catalyzes hepatocyte-to-cholangiocyte transdifferentiation, and activation of this 
pathway alleviates cholestasis in mouse models of PSC. 
3.3 Materials and Methods 
3.3.1 Animal Model 
All animal studies were performed in accordance with the guidelines of the Institutional 
Animal Care and Use Committee (IACUC) at the University of Pittsburgh School of Medicine 
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(Pittsburgh, PA) and the NIH (Bethesda, MD; protocol number 17071066). All mice were in a 
C57Bl6 background and maintained in ventilated cages under 12h light/dark cycles with access to 
enrichment, water and food ad libitum. To label cells with GFP, 8-week-old transgenic mice (TG) 
expressing a mutated non-degradable form of β-catenin in the liver and wild type controls (WT) 
were injected with 5x1011 viral particles adeno-associated virus serotype 8 carrying thyroid 
binding globulin-green fluorescent protein (AAV8-TBG-GFP, Penn Vector Core, Philadelphia, 
PA) diluted in sterile PBS. The AAV8 construct is specific for hepatocytes and does not infect 
other cell types of the liver, including biliary epithelial cells (BECs), stellate cells, or Kupffer cells. 
After a 12-day washout period, all animals were fed a control diet of standard mouse chow or 0.1% 
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet (Bio-Serv, Flemington, NJ) for 1 month. 
After the diet course was complete, mice were sacrificed, and blood serum and livers were 
collected. Livers were sectioned, fixed in 10% formalin, and processed for paraffin embedding or 
frozen in liquid nitrogen and stored at −80°C. n = 4 for WT, n = 3 for WT + DDC, n = 8 for TG, 
and n = 3 for TG + DDC. 
To permanently label hepatocytes to allow for lineage tracing during our studies TG mice 
were bred to R26-stopflox/flox-EYFP mice (ROSA) to generate TG-R26-stopflox/flox-EYFP mice 
(S45D). To label hepatocytes, 8-week-old ROSA and S45D mice were injected with 5x1011 viral 
particles adeno-associated virus serotype 8 carrying thyroid binding globulin-driven Cre 
recombinase (AAV8-TBG-Cre, Penn Vector Core, Philadelphia, PA) diluted in sterile PBS. The 
AAV8 construct is specific for hepatocytes and does not infect other cell types of the liver, 
including biliary epithelial cells (BECs), stellate cells, or Kupffer cells.  
After a 12-day washout period all animals were fed a control diet of standard mouse chow 
or or 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet (Bio-Serv, Flemington, NJ) for 
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2 months. Unfortunately, we received  a couple batches of DDC diet from Bio-Serv that were fatal 
to the ROSA after about 5 weeks of exposure, so we changed diet distributors and continued our 
long-term DDC diet study.  n = 3 ROSA, n = 3 ROSA + DDC, n = 7 S45D, and n = 7 S45D + 
DDC. 
For our long-term study, after a 12-day washout period, all animals were fed a control diet 
of standard mouse chow or 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet (Animal 
Specialty and Provisions LLC, Quakertown, PA). Animals were sacrificed after 2 months, 4 
months, and 6 months of DDC diet exposure and blood serum and livers were collected. Livers 
were sectioned, fixed in 10% formalin, and processed for paraffin embedding or frozen in liquid 
nitrogen and stored at −80°C. For 2-months DDC or normal diet, n = 7 ROSA, n = 8 ROSA + 
DDC, n = 3 S45D, and n = 6 S45D + DDC. For 4-months DDC or normal diet n = 5 ROSA, n = 9 
ROSA + DDC, n = 5 S45D, and n = 4 S45D + DDC. For 6-months DDC or normal diet, n = 6 
ROSA, n = 9 ROSA + DDC, n = 5 S45D, and n = 8 S45D + DDC. Both male and female mice 
were used for experimentation.  
3.3.2 Serum Biochemistry 
At the time of sacrifice, blood was collected, and serum was sent to the University of 
Pittsburgh Medical Center Clinical Chemistry laboratory for biochemical analysis of total and 
conjugated bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine 
transaminase (ALT). 
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3.3.3 Bile Flow Analysis 
After 2 months of control diet or Bio-Serv DDC diet exposure, ROSA mice and S45D mice 
were analyzed for alterations in bile flow. Mice were anesthetized and their common bile ducts 
were catheterized. Bile was collected and measured every minute for up to twenty minutes. The 
bile was flash frozen using liquid nitrogen and stored in cryogenic storage for future analysis. 
3.3.4 Hepatocyte Isolation and Roller Bottle Organoid Culture 
Eight-week-old R26-stopflox/flox-EYFP mice were injected with 5x1011 viral particles 
AAV8-TBG-Cre diluted in sterile PBS. After a 12-day washout period 2 mice were perfused via 
two step-collagenase perfusion as described elsewhere (263, 264). Freshly isolated hepatocytes 
from the livers were combined and added to roller bottles (850 cm2 surface) from Falcon (Franklin 
Lakes, NJ). 250 ml of MGM medium was added to the bottles, and the bottles were rotated at a 
rate of 2.5 rotations per minute and kept in an incubator maintained at 37°C, saturated humidity, 
and 5% CO2 for 21 days. Either immediately after hepatocyte isolation or 21 days in roller bottles 
cells/organoids were harvested and analyzed for cholangiocyte markers. 
3.3.4.1 Composition of the MGM Cell Culture Medium  
The media was mixed in a similar manner to a previously published media (263, 264). 
Eagle's Minimum Essential Medium (EMEM) powder, HEPES, glutamine, and antibiotics were 
purchased from Life Technologies, Inc and ITS mixture (insulin, transferrin, selenium) was 
purchased from Lonza. All other additives were cell-culture grade and purchased from Sigma-
Aldrich. MGM consisted of EMEM supplemented with purified bovine albumin (2.0 g/L), 
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galactose (2.0 g/L), ornithine (100 mg/L), proline (30 mg/L), ZnCl2 (0.544 mg/L), ZnSO4:7H2O 
(0.750 mg/L), CuSO4:5H2O (0.20 mg/L), MnSO4 (0.025 mg/L), and glutamine (5.0 mmol/L). 
Penicillin and streptomycin were added to the MGM at 100 mg/L and 100 μg/L and the MGM 
mixture was sterilized by filtration through a 0.22-μm low-protein-binding filter system, stored at 
4°C. Dexamethasone (10-6 mol/L), ITS (1.0 g/L), HGF (40 ng/ml), and EGF (20ng/ml) was added 
after filtration, immediately before use.  
3.3.5 Immunohistochemical Analysis 
Paraffin-embedded hepatic organoid tissues and liver tissues were divided into sections (4 
μm thick). Immunohistochemistry on paraffin-embedded sections was performed on hepatic 
organoids, as described elsewhere (177). Primary antibodies used were anti–cytokeratin 19 (CK19) 
antibody (31 μg/mL; TROMA-III-S; Developmental Studies Hybridoma Bank, Iowa City, IA). 
Secondary antibodies were goat anti-rat (Chemicon, Temecula, CA), and were used at 1 to 400, 
and staining was detected with 3,3′-diaminobenzidine detection systems after incubation with the 
Avidin-Biotin Complex Kit (Vector Laboratories, Burlingame, CA).  
3.3.6 Immunofluorescence Staining 
Paraffin-embedded hepatic organoid tissues and liver tissues were divided into sections (4 
μm thick). Immunofluorescence staining was performed on these paraffin-embedded sections. 
Sections were deparaffinized using 3 washes of xylene and dehydrated using a series two 100% 
ethanol washes and two 95% ethanol washes. For antigen retrieval 1x Dako Target Retrieval 
Solution (Agilent, Santa Clara, CA) was used and the slides and solution were microwaved at 60% 
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power for 6 minutes, the evaporated antigen solution was replaced, and then microwaved for an 
additional 6 minutes at 60% power. The slides were allowed to cool to room temperature, washed 
once in PBS, then the tissues were permeabilized using 0.1% Triton X-100 in PBS for 20 minutes 
at room temperature. The slides were washed three times in PBS, then the slides were blocked 
with 2% Goat serum (Abcam, Cambridge, UK) in PBST (0.1% Tween in PBS) for 30 minutes at 
room temperature. Primary antibodies anti-GFP (1:200, Abcam, Cambridge, UK), and anti-Pan 
Cytokeratin (1:200 DAKO/Agilent, Santa Clara, CA) or anti–cytokeratin 19 (CK19) antibody (31 
μg/mL; TROMA-III-S; Developmental Studies Hybridoma Bank, Iowa City, IA) were diluted in 
2% Goat serum in PBST and incubated overnight at 4ºC. Slides were washed three times in PBS, 
then secondary antibodies Alexa Fluor 555 goat anti-chicken IgG and Alexa Fluor 488 goat anti-
rabbit IgG or Alexa Fluor 488 goat anti-rat IgG diluted 1:800 in 2% goat serum in PBST were 
incubated for 2 hours at room temperature. Slides were three times with PBS, incubated with DAPI 
(1mg/100ml, Sigma, St. Louis, MO) for 30 seconds at room temperature, washed with PBS three 
more times, then coverslipped using gelvatol. Images were taken on a Nikon Eclipse Ti. 
3.3.7 Quantitative Real-Time PCR 
Total RNA was isolated from frozen liver tissue using Trizol reagent (Invitrogen, Carlsbad, 
CA). RT-PCR was performed as described elsewhere (177). Real-time PCR was performed on a 
CFX96 TouchReal-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA) using 
SYBR Green (Thermo Fisher Scientific, Pittsburgh, PA). Changes in target mRNA were 
normalized to GAPDH mRNA for each sample, and P value is presented as fold change over the 
average from three normal livers. Three samples per each condition were assayed in triplicate. 
Primer sequences are provided in Table 2. 
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Table 2. List of Primers Used for Quantitative RT-PCR Analysis in Section 3.0 
EpCAM, epithelial cell adhesion molecule; CK19, cytokeratin 19; Sox9, sex-determining region Y-box transcription 
factor 9. 
Primer name Sequence 
EpCAM (forward) 5′- GTGAATGCCAGTGTACTTCCTA-3′ 
EpCAM (reverse) 5′- GCTGTGAGTCATTTCTGCTTTC-3′ 
CK19 (forward) 5′- GACCTGGAGATGCAGATTGAG-3′ 
CK19 (reverse) 5′- GCTCCTCAGGGCAGTAATTT-3′ 
Sox9 (forward) 5′- CAGGCAAGAATTGGGCAAAG-3′ 
Sox9 (reverse) 5′- CCTCCCAACACGCAGTAAA-3′ 
3.3.8 Diet Comparison Study 
To compare the DDC diet used in this study diet DDC diet used in previous studies, eight-
week-old C57BL/6J (WT), ROSA, and S45D mice were placed on either 0.1% DDC diet from 
Animal Specialty and Provisions LLC or 0.1% DDC diet from Bio-Serv for 2 months. After 2 
months on diet mice were sacrificed and blood serum and livers were collected. n= 3 WT + Animal 
Specialty, n = 3 WT + Bio-Serv, n= 5 ROSA + Animal Specialty, n= 3 ROSA + Bio-Serv, n= 3 
S45D + Animal Specialty, n=3 S45D + Bio-Serv.  
3.3.9 Statistical Analysis 
Data are presented as means, SD, and/or individual data points. Data were analyzed, and 
graphs were generated using Prism GraphPad 9.0 (GraphPad Software, San Diego, CA). P values 
were determined using the two-tailed t-test, one-way analysis of variance followed by an 
appropriate post hoc test, or two-way analysis of variance followed by the appropriate post hoc 
test. P < 0.05 was considered statistically significant. 
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3.4 Results 
3.4.1 After 1 Month of Bio-Serv DDC exposure TG mice have more cholangiocyte marker 
expressing hepatocytes than WT mice  
Before we permanently labeled hepatocytes with EYPF, we performed an initial pilot study 
utilizing AAV8-TBG-GFP, which would only label the cells that were infected with the virus and 
not their progeny. We treated WT mice and TG with AAV8-TBG-GFP and then exposed them to 
Bio-Serv DDC diet for 1 month. After 1 month of Bio-Serv DDC diet exposure we found that both 
WT and TG mice have elevated serum biochemical markers for both biliary and hepatic injury. 
Both WT and TG mice on DDC diet have equally high levels of alkaline phosphatase (ALP), 
conjugated bilirubin, and total bilirubin (Figure 19A), which indicates that both mice have 
comparable biliary injury. Similarly, both types of mice also have equally high serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels (Figure 19B) as well, which 
indicates that both mice have comparable levels of hepatic injury. These results are expected, since 
DDC is known to induce biliary and subsequent hepatic injury in mice. 
However, despite there being no differences in serum markers of injury, we noted that after 
1 month of DDC diet exposure TG mice started to show more hepatocytes positive for a 
cholangiocyte marker, Pan-Cytokeratin (PanCK), compared to WT mice on DDC diet (Figure 
19C). These PanCK positive hepatocytes in the TG mice exposed to DDC diet also appear to be 
forming duct like shapes, which are not present in the WT mice on DDC diet (Figure 19C). 
Unfortunately, this study was not pursued further since the labeling method used to monitor the 
hepatocyte-to-cholangiocyte transdifferentiation in this model was not permanent. 
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Figure 19. After 1 Month of Bio-Serv DDC exposure TG mice have more cholangiocyte marker expressing 
hepatocytes, but similar biliary and hepati injury compared to WT mice exposed to DDC diet 
After 1 month exposed to Bio-Serv DDC diet WT and TG mice have similar levels of blood serum biliary injury 
markers (A) alkaline phosphatase (ALP), conjugated bilirubin, and total bilirubin and hepatic injury markers (B) 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST). (C) After 1 month of Bio-Serv TG had more 
cholangiocyte marker expressing hepatocytes and hepatocytes forming bile duct-like shapes compared to WT mice 
exposed to DDC diet. Red circles indicate hepatocytes forming duct-like shaped. Cells were labeled with GFP using 
AAV8-TBG-GFP. (x200) 
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3.4.2 Mouse Hepatocytes Reprogram to Cholangiocyte in In Vitro Organoid Models 
To demonstrate hepatocytes’ capability to convert to cholangiocytes and the practicality of 
our lineage tracing model, we isolated primary hepatocytes permanently labeled with EYFP from 
8-week-old ROSA mice, and utilized them to create hepatic organoids. We found that after 21 
days of culture, cholangiocyte developed in hepatic organoids as seen in a CK-19 stain (Figure 
20A). These findings were further confirmed through a QPCR analysis of the cholangiocyte 
markers EpCAM, Sox9, and CK19 (Figure 20B). In organoids cultured for 21 days all three 
cholangiocyte markers were significantly increased compared to hepatocyte isolated before being 
cultured to develop the organoids (Figure 20B). These findings indicate that the cholangiocytes 
present were likely functional, as fully converted cholangiocytes rather than cholangiocyte-like 
hepatocytes. Finally, the cholangiocytes present in these organoids were also hepatocyte-derived 
cholangiocytes, not the contaminating cholangiocytes that can make it through the hepatocyte 
isolation process. In the organoids the cholangiocyte population present were EYFP positive, 
indicating these cholangiocytes were derived from the EYFP positive hepatocytes and not native 
cholangiocytes that contaminate the hepatocyte isolation (Figure 20C). This study helps to 
demonstrate that our lineage tracing model is a viable method to follow hepatocyte-to-
cholangiocyte conversion and it solidifies the ability of hepatocytes to convert to cholangiocytes. 
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Figure 20.Cholangiocytes present in hepatic organoids are hepatocyte-derived  
(A) Representative cytokerain 19 (CK19) image shows that hepatic organoids develop a cholagioncyte layer after 21 
days of culture (x100, insert x200), (B) Quantitative RT-PCR analysis of epithelial cell adhesion molecule (EpCAM), 
sex-determining region Y-box transcription factor 9 (Sox9), and cytokeratin 19 (CK19) demonstrates that organoids 
culutred for 21 days have increased cholaginocyte markers compared to day 0 isolated primary hepatocytes, (C) 
Representative EYFP, pan-cytokeratin (PanCK), and merged images show that cholangiocytes present in organoid 
culture are hepatocyte derived and not from native contaminating cholangiocytes (x200). ∗∗∗P < 0.001 
3.4.3 S45D Mice exposed to Bio-Serv DDC Diet for 2 Months have Increased Bile Flow 
After determining our lineage tracing model would work to monitor hepatocyte-to-
cholangiocyte transdifferentiation we then moved into a mouse model to see how β-catenin activity 
would affect the rate of hepatocyte conversion and severity of biliary injury. To study this, we 
placed ROSA or S45D mice on Bio-Serv DDC diet with the intent to perform a long-term study 
and collecting timepoints at 2, 4, and 6 months of DDC diet exposure. Unfortunately, we were not 
able to utilize Bio-Serv DDC diet to do so, as we received several batches of DDC diet from Bio-
Serv that were fatal to ROSA mice after 5 weeks on diet, which led us to change diet 
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manufacturers. However, before the Bio-Serv diet started to kill the ROSA mice we did manage 
to get some ROSA mice to 2 months on Bio-Serv DDC. During this time, we performed a bile 
flow study on these mice to determine if β-catenin expression helped to promote hepatocyte 
reprogramming and if those reprogrammed hepatocytes assisted with bile flow in these DDC 
exposed mice. Interestingly S45D mice on Bio-Serv DDC diet for 2 months have the fastest bile 
flow, over all timepoints, compared to S45D on control diet and ROSA mice both on and off of 
DDC diet (Figure 21). ROSA mice on Bio-Serv DDC diet had the slowest bile flow (Figure 21). 
These findings indicate that S45D mice after 2 months of Bio-Serv DDC diet exposure likely have 
more cholangiocyte-like hepatocytes, or hepatocytes that have converted to cholangiocytes.  
 
Figure 21. Bile flow is increased in S45D mice after 2 months of Bio-Serv DDC diet exposure 
After 2 months of normal or DDC diet exposure the common bile duct of ROSA or S45D was canaliculated and bile 
flow was measured in µl/min for 20 miutes. S45D mice on DDC diet had significantly increased average bile flow 
(left graph) and and bile flow at individual time points (right graph) compared to ROSA mice on DDC diet. ∗∗∗P < 
0.001 
 
To determine if S45D had more hepatocyte-derived ducts allowing for better bile flow we 
analyzed these livers for EFYP positive cholangiocytes. We found that after 2 months on Bio-Serv 
DDC diet, S45D mice do have EYFP positive, hepatocyte-derived cholangiocytes present and 
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these cells were integrated into the bile ducts (Figure 22). Unfortunately, we were unable to collect 
ROSA mice at this time point on the Bio-Serv diet as well to image for comparison to the S45D 
mice, since the livers used for the bile flow study could not be utilized for imaging. These findings 
were promising, and we wanted to study how this hepatocyte reprogramming was affected during 
long-term DDC diet exposure, so we decided to change DDC diet manufacturers in the hope that 
the new manufacturer would not be fatal to the ROSA mice as well. 
 
Figure 22. S45D mice on Bio-Serv DDC diet for 2 months have hepatocyte-derived cholagniocytes present 
S45D mice fed DDC Bio-Serv DDC diet for 2 months have EYFP positive, hepatocyte-derived cholagnaiocytes 
integrated into the bile ducts. (x200) 
3.4.4 Biliary Injury Improves Over Time in Mice Fed DDC Diet Long-Term 
After changing diet producers and the ROSA mice surviving to 2 months and longer on 
DDC diet, we found that regardless of β-catenin activity, mice exposed to DDC diet long term had 
improved cholangiocyte injury over time. This can be observed in the decrease of serum ALP, 
conjugated bilirubin, and total bilirubin of both the ROSA and S45D mice fed DDC over time 
(Figure 23A). Both ROSA and S45D mice on DDC diet have the highest level of biliary injury at 
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2 months, which steadily decrease as time progresses, with their lowest level of biliary injury being 
at 6 months, as seen in their serum ALP, conjugated bilirubin, and total bilirubin (Figure 23A). 
ROSA mice following a similar trend of decreasing biliary injury as the S45D mice which was 
unexpected, since previous studies show that biliary injury remains high in control mice exposed 
to long term DDC diet (180). 
Unlike biliary injury, hepatic injury remains high in both ROSA and S45D mice fed DDC 
diet. This is observed in the levels of serum ALT and AST in both mice on DDC diet (Figure 23B). 
At all-time points both ROSA and S45D mice on DDC diet have increased serum ALT and AST 
indicated that hepatic injury remains high in both mouse types (Figure 23B). This is not 




Figure 23. Biliary injury improves over time, but hepatic injury remains high in both ROSA and S45D mice 
fed DDC diet 
(A) Blood serum levels of alkaline phosphatase (ALP), conjugated bilirubin, and total bilirubin shows as DDC diet 
exposure increases biliary injury decreases in both ROSA and S45D mice, whereas (B) serum levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) indicate that hepatic injury remains high at all time 
points in both ROSA and S45D mice fed DDC diet. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ****P < 0.0001  
3.4.5 DDC Diet Exposure Promotes Increased Hepatocyte Reprogramming in S45D 
Transgenic Mice  
After determining that biliary injury improves in both S45D and ROSA mice exposed to 
DDC over time, we then decided to see if this improvement was related to hepatocyte-to-
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cholangiocyte transdifferentiation. Utilizing the lineage tracing method we established in our in 
vitro organoid study we were able to observe whether cholangiocytes were derived from 
hepatocytes or not. After 2 months of DDC diet exposure both ROSA and S45D mice did not have 
any EYFP positive, hepatocyte-derived cholangiocyte (Figure 24). After 4 months of DDC diet 
exposure, both ROSA mice and S45D mice started to have EYFP positive, hepatocyte-derived 
cholangiocytes present in their bile ducts (Figure 24). Interestingly, S45D mice on DDC diet for 4 
months tended to have more hepatocyte-derived cholangiocytes compared to ROSA mice on DDC 
diet and also started to have small bile ducts completely consisting of hepatocyte-derived 
cholangiocytes. This trend of hepatocyte-derived cholangiocytes only increased with DDC diet 
exposure in both ROSA and S45D mice. After 6 months of DDC diet both types of mice had even 
more EYFP positive, hepatocyte-derived cholangiocytes present in their bile ducts than they did 
after 4 months of diet exposure (Figure 24). However, S45D mice on DDC diet for 6 months had 
significantly more EYFP positive cholangiocytes than ROSA mice on DDC diet for 6 months. The 
S45D mice also had whole EYFP positive bile ducts, while the ROSA mice did not (Figure 24). 
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Figure 24. As DDC diet exposure increases S45D mice have more hepatocyte-derived choalginocytes present 
than ROSA mice 
Representative EYFP, cytokeratin 19 (CK19) and DAPI images (top) and the precentage of EYFP positive 
cholaginocytes (bottom) in ROSA mice and S45D mice fed DDC diet for 2, 4, and 6 months. The red circle in the 
S45D + DDC at 2 months indicates a small bile duct that consists completely of hepatocyte-derived cholaginocytes 
(x200). ∗∗∗∗P < 0.0001 
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3.4.6 DDC Diet Producers Induce Differing Levels of Biliary Injury in ROSA and S45D 
Mice 
After comparing our results to previous findings, we noted that our long-term diet studies 
did not yield the similar results to those previously published (180). Therefore, we decided to do 
a DDC diet comparison between the Animal Specialty DDC diet and the Bio-Serv DDC diet to 
determine if diet manufacturers can affect biliary injury. Interestingly we found that after ordering 
a new batch of DDC diet from Bio-Serv, after we had completed our long-term study using Animal 
Specialty DDC diet, ROSA mice were able to survive past 5 weeks on the Bio-Serv diet. We also 
found that the different diet manufacturers do yield different levels of biliary injury in the mice 
fed DDC diet for 2 months. ROSA mice on Bio-Serv DDC diet have increased serum ALP, 
conjugated, and total bilirubin compared to ROSA mice on Animal Specialty DDC diet (Figure 
25A). S45D mice on Bio-Serv DDC diet have decreased serum ALP and equal conjugated and 
total bilirubin compared to S45D mice on Animal Specialty DDC diet (Figure 25A). However, 
unlike biliary injury, hepatic injury markers were not altered by the different diet producers in the 
ROSA and S45D mice. Both ROSA and S45D mice on both types of DDC diet had consistently 




Figure 25. After 2 months of exposure to DDC diets from different producers ROSA and S45D mice have 
differing levels of biliary injury, but comparable levels of hepatic injury 
(A) Blood serum levels of alkaline phosphatase (ALP), conjugated bilirubin and total bilirubin show that DDC diet 
produced by Bio-Serv casues increased levels of biliary injury in ROSA mice and decrased levels of biliary injury in 
S45D mice compared to Animal Specilaty DDC diet. (B)Sserum levels of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) indicate that hepatic injury remains high in both DDC diet types in both ROSA and 
S45D mice. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ****P < 0.0001  
3.5 Discussion 
Wnt/β-catenin activity may be protective in a subset of patients with cholestatic liver 
disease. A previous study found that transgenic mice (TG) expressing a mutated, nondegradable 
form of β-catenin after long-term treatment with DDC diet had decreased serum ALP, a serum 
marker used by clinicians to monitor PSC patients and their disease progression (180). These TG 
mice exposed to long-tern DDC diet also had significantly more A6, a cholangiocyte marker, 
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positive hepatocytes than the WT control on DDC diet (180). These findings led us to our 
hypothesis β-catenin signaling will induce hepatocyte-to-cholangiocyte transdifferentiation 
alleviating cholestatic injury. Excitingly using our lineage tracing model we found that S45D 
transgenic mice on DDC diet did have significantly more hepatocyte-derived cholangiocytes than 
ROSA mice after 6 month of DDC diet. We also found that these hepatocyte-derived 
cholangiocytes appeared to form their own ducts in the S45D mice, while the hepatocyte-derived 
cholangiocytes in the ROSA mice appeared to integrate into already existing bile ducts. These 
findings support our hypothesis and indicate that β-catenin does promote hepatocyte-to-
cholangiocyte transdifferentiation. 
However, something that was unexpected during our study was the trend the biliary injury 
serum markers followed in the ROSA mice exposed to DDC diet. Surprisingly, not only did biliary 
injury serum markers decrease in S45D mice on DDC diet over time, they also decreased in the 
ROSA mice exposed to DDC diet. This was unexpected because in a previous study, it was found 
that after 150 days of DDC diet, TG mice  had significantly decreased biliary injury compared to 
the WT mice (180). In the mice exposed to long term DDC diet, WT mice had total bilirubin that 
was trending towards increased levels compared to TG mice (Figure 26). This study also found 
that WT mice had significantly higher levels of serum ALP after long-term DDC exposure 
compared to TG mice (Figure 26). Both of these results indicate that WT mice exposed to DDC 
diet long-term had increased biliary injury compared to TG mice exposed to DDC diet long-term. 
These findings were partially the reasoning for our initial hypothesis, so when we did not see this 
data recapitulated in our own findings we were surprised. 
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Figure 26. Transgenic mice have decreased biliary injury compared to WT mice after 150 days of DDC diet 
exposure 
A graphicial representation of data collected in a previous study performed by Thompson MD et al., which found that 
after long-term DDC diet exposure (150 days) mice transgenic (TG) for non-degradable S45D-mutated β-catenin in 
the liver have decreased serum total bilirubin and alkaline phosphatase (ALP) compared to WT mice (180). ∗P < 0.05 
 
One possible explanation for our ROSA mice not having increased biliary injury compared 
to our S45D mice is the DDC diet we used in this study. The previous study used a DDC diet 
produce by the company Bio-Serv, which we initially intended to put our mice on as well. 
However, our ROSA mice would not survive longer than 5 weeks on the Bio-Serv DDC diet. This 
was unusual since other studies had managed to keep WT mice on diet for much longer, so we 
were perplexed as how to continue our long-term DDC diet studies. The WT/ROSA mice not 
surviving longer than 5 weeks on the Bio-Serv diet continued through two distinctly different 
batches of Bio-Serv DDC diet and us contacting the company to see if anything had changed in 
their diet making procedure to try to determine why this was occurring. After being reassured by 
Bio-Serv that nothing had changed in the diet making process, we assumed the mice not surviving 
on the Bio-Serv diet was something that was out of our control and found a new DDC diet 
producer. Luckily for our study the DDC diet from our new diet producers, Animal Specialty and 
Provisions LLC, did not kill the control mice after 5 weeks of exposure and we were able to keep 
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the mice alive for the long-term diet studies. However, after analyzing the serum results from our 
ROSA and S45D mice we were surprised to find that the ROSA control mice had decreasing serum 
biliary injury markers much like the S45D mice. We determined these changes in control serum 
levels was likely due to the difference in the diet producers. Therefore, we decided to do a 
comparison of the DDC diet produced by Bio-Serv and Animal Specialty and Provisions LLC to 
see how the different DDC diets affect serum results in our ROSA and S45D mice after 2 months 
of exposure.  
Surprisingly, we found that different DDC diet manufacturers do yield different results in 
the mice exposed to the diet for 2 months. ROSA mice on Bio-Serv DDC diet have increased 
biliary injury compared to ROSA mice on Animal Specialty DDC diet. S45D mice on Bio-Serv 
DDC diet have decreased biliary injury markers compared to S45D mice on Animal Specialty 
DDC diet. However, unlike biliary injury, hepatic injury markers were not altered by the different 
diet producers in either genotype. 
 These results indicate that DDC diet from different producers cause different levels of 
biliary injury. Therefore, it seems that Bio-Serv would be a better DDC diet producer for this study 
than Animal Specialty. This is because the ROSA mice on Bio-Serv DDC diet have higher biliary 
injury after 2 months on diet compared to S45D mice, which is similar to the long-term results 
seen in the previous study  (Figure 26) (180). This is also enlightening, since a comparison of the 
DDC diet producers has not been previously studied. In this comparison we show that feeding 
mice DDC diet from these different producers can alter the serum results, which can ultimately 
affect the final results of a study. These findings lead us to believe that long-term exposure to 
Animal Specialty diet does not yield the same results in control animals that long-term exposure 
 85 
to Bio-Serv diet does because the initial injury caused by the Animal Specialty diet is not as high 
the Bio-Serv diet. 
Additionally, our pilot study utilizing AAV8-TBG-GFP and WT and TG on Bio-Serv DDC 
diet for 1 month showed that TG mice on DDC diet have more hepatocytes positive for 
cholangiocyte markers forming duct like shapes compared to WT mice on DDC diet. 
Unfortunately, this study was not pursued further since the labeling method used to monitor the 
hepatocyte-to-cholangiocyte transdifferentiation in this model was not permanent. However, this 
study and these findings did lead us to create and use the ROSA and S45D mice, which allowed 
us to permanently label hepatocytes with EYFP and monitor hepatocyte-to-cholangiocyte 
transdifferentiation more effectively. 
Also of note, we did manage to get some ROSA mice to 2 months on Bio-Serv DDC diet 
before we received the batches of diet that caused the ROSA mice to die. During this time, the bile 
flow study performed on these mice showed that S45D mice on Bio-Serv DDC diet for 2 months 
have the fastest bile flow and the ROSA mice on Bio-Serv DDC diet had the slowest bile flow. 
These findings indicate that S45D mice after 2 months of Bio-Serv DDC diet exposure likely have 
more cholangiocyte-like hepatocytes or hepatocytes that have converted to cholangiocytes, which 
can be observed to an extent. S45D mice do have EYFP positive, hepatocyte-derived 
cholangiocytes present in and integrated into the bile ducts, unfortunately we were unable compare 
these results to ROSA mice. However, if the bile flow findings are indicative, it is likely the ROSA 
mice would not have any or very few hepatocyte-derived cholangiocytes. This is because these 
hepatocyte-derived cholangiocytes are likely helping to create new bile flow channels allowing 
bile to better escape the liver, which is why the S45D mice on DDC have increased flow. The 
ROSA mice likely have decreased bile flow because the hepatocytes are not being driven to 
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transdifferentiate, since these mice do not have β-catenin activity like the S45D mice. All of these 
preliminary findings, using Bio-Serv DDC diet, indicate that if injury is higher earlier, as is caused 
by Bio-Serv DDC diet, β-catenin activity does drive hepatocyte-to-cholangiocyte 
transdifferentiation, starting around 2 months of DDC diet exposure. However, it is currently 
unknown how transdifferentiation is affected in both the ROSA and S45D mice beyond 2 months 
and if the hepatocyte-derived cholangiocytes remain cholangiocytes on long term DDC diet 
exposure. Therefore, it is necessary that all previous experiments using Animal Specialty DDC 
diet must be performed again using Bio-Serv DDC diet, since the diets have been shown to yield 
different results at 2 months of exposure. 
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4.0 Wnt7b Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis 
In this section we characterize the effects Wnt7b β-catenin independent signaling has 
cholangiocyte proliferation during cholestatic injury. We predict that mice lacking Wnt7b in their 
cholangiocyte compartment and cholangiocyte and hepatocyte compartments will have 
exacerbated biliary injury after DDC diet exposure compared to control mice exposed to DDC 
diet. We will discuss our results and interpretations in detail.  
4.1 Paper Summary 
Previously we identified an upregulation of specific Wnt proteins in the cholangiocyte 
compartment during cholestatic liver injury and found that mice lacking Wnt secretion from 
hepatocytes and cholangiocytes showed fewer proliferating cholangiocytes and high mortality in 
response to 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet, a murine model of PSC. In 
vitro studies demonstrated that Wnt7b, one of the Wnts upregulated during cholestasis, induces 
proliferation of cholangiocytes in an autocrine manner and increases secretion of pro-inflammatory 
cytokines. Therefore, we hypothesized that loss of Wnt7b may exacerbate some of the 
complications of cholangiopathies by decreasing the ability of bile ducts to induce repair. Wnt7b-
flox mice were bred with Krt19-cre mice to deplete Wnt7b expression in only cholangiocytes (CC), 
or with Alb-cre mice to delete Wnt7b expression in both hepatocytes and cholangiocytes (HC + 
CC). These mice were placed on DDC diet for one month then sacrificed for evaluation. Contrary 
to our expectations, we found that mice lacking Wnt7b from CC and HC + CC compartments had 
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improved biliary injury, but equivalent hepatic injury compared to controls. CC KO had sustained 
expression of biliary markers such as EpCAM, Sox9, and CK-19 and decreased fibrosis compared 
to control and HC + CC KO mice despite decreased cholangiocyte proliferation. CC and HC + CC 
KO mice on DDC diet also had more hepatocytes expressing cholangiocyte markers compared to 
WT mice on DDC diet, indicating that Wnt7b suppression promotes hepatocyte reprogramming. 
Conclusion:  Wnt7b induces a pro-proliferative, pro-inflammatory program in cholangiocytes, 
and its loss is compensated for by conversion of hepatocytes to a biliary phenotype during 
cholestatic injury. 
4.2 Background 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder that is 
characterized by inflammation and fibrosis of the bile ducts, which can lead to end-stage liver 
disease and reduced life expectancy. Because the etiology of this disease is not fully understood, 
effective medical therapies are scarce and, in most cases, the only life extending treatment 
currently available is liver transplantation. Of the patients fortunate enough to receive a liver 
transplant up to 20% will have recurrence of disease (159, 265, 266). Therefore, an effective 
treatment for PSC is critically needed, as the demand for organs available for transplant increases 
each year.  
It is well known the liver is the only internal organ capable of regeneration; however, the 
bile duct is often overlooked when touting the liver’s regenerative ability. Much like hepatocytes, 
cholangiocytes, the epithelial cells that comprise the bile ducts, also exhibit a remarkable ability 
to regenerate. Following injury, cholangiocytes proliferate to form the tubular structures necessary 
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to ensure bile modification and transport. The restitution of these biliary networks is critical in 
maintaining liver function and preventing further injury due to cholestasis. During regeneration 
after acute liver injury, hepatocytes and cholangiocytes typically proliferate to repopulate their 
own cell types. However, during severe biliary or hepatic injury, regeneration of one of the two 
epithelial cell compartments can become compromised. This is when a secondary method of 
regeneration can occur: hepatocyte-to-cholangiocyte or cholangiocyte-to-hepatocyte 
transdifferentiation (221, 224, 225, 267). These two cell populations can become and act as 
facultative stem cells for one another, interconverting to maintain tissue integrity (217). Thus, a 
therapy that induces a healthy cholangiocyte population, either from hepatocyte-derived 
cholangiocytes or native cholangiocytes, to proliferate and repair bile ducts could be a crucial 
treatment for patients suffering from cholestatic liver diseases.  
The Wnt/β-catenin signaling pathway is an important regulatory axis in liver physiology 
and pathology, due in large part to its role as a promoter of regeneration and repair (245). Recent 
studies have also demonstrated that Wnts are expressed during biliary disease as well. Activation 
of Wnt signaling is seen in the livers of PSC patients, and Wnt ligands are associated with 
proliferating biliary cells in 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet, a model for 
biliary injury and chronic cholestasis (202, 268). Other studies have shown upregulation of specific 
Wnts in cholangiocytes after DDC diet, and in a mouse model of cholangiocarcinoma, these 
ligands induced cholangiocyte proliferation (78, 269). Our lab has also shown that Wnt proteins 
are expressed in the cholangiocyte population during cholestatic liver injury, and that mice lacking 
Wnt secretion from both hepatocytes and cholangiocytes had fewer proliferating cholangiocytes 
and high mortality in response to DDC diet (69). However, a recent manuscript has shown that 
during biliary injury cholangiocytes produce Wnts that promote the formation of ductal scars by 
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acting via the Wnt-PCP pathway to induce fibrogenic cytokine production (270). Therefore, 
further mechanistic analyses are needed to determine the role of specific Wnts in the process of 
biliary injury and repair. 
One of the Wnts that has been identified to be upregulated during cholestasis is Wnt7b, 
which was shown to induce cholangiocyte proliferation in an autocrine manner independent of β-
catenin activity (69, 269). Therefore, we hypothesized that loss of Wnt7b may exacerbate some of 
the complications caused by cholangiopathies by decreasing the ability of bile ducts to induce 
repair. To test this hypothesis, we created both cholangiocytes (CC)-specific Wnt7b knockouts 
(KO) or KO in which Wnt7b is deleted from both hepatocytes and cholangiocytes (HC + CC) and 
subjected these mice to cholestatic liver injury. We found that both CC KO and HC + CC KO mice 
had improved biliary injury; however, this is not due to changes in ductular mass but rather to 
increased numbers of hepatocytes expressing biliary markers, which compensates for the inability 
of cholangiocytes to proliferate due to the lack of Wnt7b.  
4.3 Materials and Methods 
4.3.1 Cell Lines, Transfection, and Luciferase Assay  
Small cell cholangiocytes (SMCCs) were plated at 2x105 cells/well in a 6 well plate and 
transfected with 2.5 µg control or Wnt7b plasmid, described elsewhere (69), and 50µM negative 
or β-catenin siRNA (Thermo Fisher Scientific, Waltham, MA) using Lipofectamine 3000 
(Invitrogen, Carlsbad, CA), as per the manufacturer’s instructions. Cell proliferation was measured 
48 hours post transfection using a colorimetric cell viability kit I (WST-8) (PromoCell, Heidelberg, 
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Germany) or thymidine incorporation assay as described previously (271). Along with the control 
and Wnt7b plasmids, cells were also transfected with 2.5 µg of a luciferase TOPFlash plasmid 
(Upstate Biotechnology, Lake Placid, NY)(69) using Lipofectamine 3000. 48 hours post 
transfection, luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI), as per the manufacturer’s instructions. 
For the ELISA array, SMCCs were plated and transfected with control or Wnt7b plasmid 
as described above. 24 hours post-transfection cell media was changed, and 48 hours later, the now 
conditioned media was collected and analyzed using the chemiluminescent per the manufacturer’s 
instructions. WST-8, luciferase assay, and ELISA assay results were collected using a Synergy™ 
HTX Multi-Mode Microplate Reader from BioTek Instruments. 
4.3.2 Animal Models  
All animals were housed in light- and temperature-controlled facilities and maintained in 
accordance with the Guide for Care and Use of Laboratory Animals and the Animal Welfare Act, 
and all studies were performed in accordance with the guidelines of the Institutional Animal Use 
and Care Committee at the University of Pittsburgh School of Medicine and the National Institutes 
of Health (protocol number 20077675). Control mice (K19CreERT/Rosa-stopflox/flox-EYFP) were 
produced by breeding K19CreERT (Jackson Laboratories, Bar Harbor, ME) with Rosa-stopflox/flox-
EYFP (Jackson Laboratories, Bar Harbor, ME). CC KO mice (K19CreERT/Rosa-stopflox/flox-EYFP/ 
Wnt7bc3 mice) were produced by breeding the control K19CreERT/Rosa-stopflox/flox-EYFP mice with 
Wnt7bc3 mice (Jackson Laboratories). HC + CC KO mice (Albumin-Cre/ Rosa-stopflox/flox-EYFP/ 
Wnt7bc3) were produced by breeding the Rosa-stopflox/flox-EYFP mice with  Wnt7bc3 mice, then 
breeding the Rosa-stopflox/flox-EYFP/Wnt7bc3 offspring with Albumin-Cre+/- mice (Jackson 
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Laboratories, Bar Harbor, ME). To delete Wnt7b and label cholangiocytes in K19CreERT/Rosa-
stopflox/flox-EYFP/ Wnt7bc3 mice, 3 doses of 10 mg/kg tamoxifen were given every other day 
starting at 21 days old. At 8 weeks of age all mice were then placed on 0.1% 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC) diet (Animal Specialties and Provisions LLC, Quakertown, PA) or 
left on standard mouse chow as a control for 1 month. Mice were then sacrificed, and livers and 
blood serum collected. Livers were divided and fixed in 10% formalin and processed for paraffin 
embedding, or frozen in liquid nitrogen and stored at −80 °C. For WT on control diet n = 10, for 
WT on DDC diet n = 6, for CC KO on control diet n = 13, for CC KO on DDC diet n = 8, for HC 
+ CC KO on control diet n = 4, and for HC + CC KO on DDC diet n = 8. Both male and female 
mice were used for experimentation. All mice were in a C57Bl6 background and maintained in 
ventilated cages under 12h light/dark cycles with access to enrichment, water and either standard 
chow or DDC diet ad libitum. 
4.3.3 Serum Biochemistry  
Blood serum was sent to and biochemically analyzed by The University of Pittsburgh 
Medical Center Clinical Chemistry lab. Alkaline phosphatase (ALP), aspartate aminotransferase 
(AST), alanine transaminase (ALT), total bilirubin and direct bilirubin were measured in all 
samples.  
4.3.4 Immunohistochemical Analysis 
Paraffin-embedded liver tissues were sectioned at 4 μm thick. Sections were stained with 
hematoxylin and eosin (H&E) or Picro-Sirius Red (Abcam, Cambridge, UK) and Sirius red images 
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were quantified using ImageJ Fiji ImageJ Fiji (version 2.0.0-rc-68/1.521; 
https://imagej.nih.gov/ij/). Images were split into red, green and blue channels, and the green 
channel was selected for further analysis due to the optimal color separation of the staining. The 
fibrotic regions were isolated by using the Threshold setting 0 for the upper level and 145 for the 
lower level. The percentage of the stained area to the total image was determined. Five images per 
mouse liver (n=3 mice) were quantified for each genotype and diet. 
Immunohistochemistry on paraffin-embedded sections was performed on mouse livers as 
described elsewhere.(177) Primary antibodies used were A6 (26 µg/ml DSHB, University of Iowa) 
and PCNA antibody (1:4000, Santa Cruz Biotechnology, Dallas, TX). Secondary antibodies were 
goat anti-rabbit, and donkey anti-goat (Chemicon, Temecula, CA) and were used at 1:400, and 
staining was detected with 3,3′‐diaminobenzidine detection systems after incubation with the 
Avidin–Biotin Complex Kit (Vector Laboratories, Burlingame, CA). For immunofluorescence 
staining the primary antibodies were anti-GFP (1:200, Abcam, Cambridge, UK) and Anti-
Cytokeratin (1:200 DAKO, Glostrup, Denmark) and the secondary antibodies were Alexa Fluor 
555 goat anti-chicken IgG (1:500, Invitrogen) and Alexa Fluor 488 goat anti-rabbit IgG (1:500, 
Invitrogen). Images were taken on a Nikon Eclipse Ti.  
Ductular response was quantified using A6 IHC stains using ImageJ Fiji in a similar 
manner to quantify fibrosis. For A6 IHC blue channel was selected for further analysis due to the 
optimal color separation and the A6 positive regions were isolated by using the Threshold setting 
50 for the upper lever and 115 for the lower level. These Threshold levels allowed for 
quantification of only stained cells and not porphyrin plugs caused by DDC exposure. The 
percentage of the stained area to the total image was determined. Five images per mouse liver (n=3 
mice) were quantified for each genotype and diet. 
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4.3.5 Quantitative Real-Time PCR  
Total RNA was isolated from frozen liver tissue using a tissue Homogenizer150 (Thermo 
Fisher Scientific) and Trizol reagent (Invitrogen). Reverse-transcription PCR was performed as 
described elsewhere (177). Real-time PCR was performed using SYBR Green (Thermo Fisher 
Scientific) on a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA). Changes in target mRNA were normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA for each sample. P values are presented as fold change over the 
average from 3 normal livers. Each sample was run in triplicate. Sequences of primers are available 
in Table 3. 
Table 3. Primers used for quantitative RT-PCR analysis in Section 4.0 
CK19, cytokeratin 19; Sox9, sex-determining region Y-box transcription factor 9; EpCAM, epithelial cell adhesion 
molecule. 
Primer name Sequence 
Wnt7b (forward) 5′-ACCGCATGAAGCTGGAATGTA-3′ 
Wnt7b (reverse) 5′-CCTCGCGGAACTTAGGTAGC-3′ 
Wnt7b Exon 3 (forward) 5′-CAGCTACGCAGCTACCAGAA-3′ 
Wnt7b Exon 3 (reverse) 5′-GTCCTCCTCGCAGTAGTTGG-3′ 
β-catenin (forward) 5′-GGGTCCTCTGTGAACTTGCTC-3′ 
β-catenin (reverse) TTCTTGTAATCCTGTGGCTTGTCC-3′ 
CK19 (forward) 5′-GACCTGGAGATGCAGATTGAG-3′ 
CK19 (reverse) 5′-GCTCCTCAGGGCAGTAATTT-3′ 
Sox9 (forward) 5′-CAGGCAAGAATTGGGCAAAG-3′ 
Sox9 (reverse) 5′-CCTCCCAACACGCAGTAAA-3′ 
EpCAM (forward) 5′-GTGAATGCCAGTGTACTTCCTA -3′ 
EpCAM (reverse) 5′-GCTGTGAGTCATTTCTGCTTTC-3′ 
Wnt7a (forward) 5′-CGGACGCCATCATCGTCATA-3′ 
Wnt7a (reverse) 5′-CAGTTCCAACGGCCATTTCG -3′ 
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4.3.6 Protein Extraction and Western Blot Analysis 
Proteins were extracted, and Western blot analysis was performed as previously described 
(242). Briefly, proteins were extracted from whole-cell liver lysates, and denatured proteins were 
separated on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. 
Membranes were blocked using 5% nonfat dry milk or 5% bovine serum albumin in 0.1% Triton 
X-100 in Tris-buffered saline and incubated with primary antibodies (diluted in 3% blocking 
media). The following primary antibodies were used: glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; 1:5000; Invitrogen, Carlsbad, CA), purified mouse anti–β-catenin (1:500; BD 
Biosciences, San Jose, CA), nonphosphorylated (active) β-catenin (Ser33/37/Thr41) (1:1000; Cell 
Signaling Technology, Danvers, MA), and phosphorylated β-catenin (Ser675; D2F1; 1:1000; Cell 
Signaling Technology). Horseradish peroxidase–conjugated secondary antibodies (1:20,000 
diluted in 3% blocking media; Santa Cruz Biotechnology) were used and blots were visualized 
using the Enhanced Chemiluminescence System (GE Healthcare, Little Chalfont, UK). 
4.3.7 Confocal microscopy and image analysis of mRNA expression by RNAscope 
 In situ detection of GFP, WNT7b, and glutamine synthetase mRNA expression was 
achieved by using the RNAscope kit (Advanced Cell Diagnostics, Hayward, CA) according to the 
manufacturer’s protocol. Glutamine synthetase served as a positive control. In short, fixed frozen 
liver sections were pretreated with protease and incubated with probe targeting Wnt7b, GFP, and 
Glul (glutamine synthetase) (Advanced Cell Diagnostics) for 2h at 40C. The slides were washed 
using wash buffer (Advanced Cell Diagnostics) at room temperature after each hybridization step, 
and lastly DAPI (Advanced Cell Diagnostics) was applied for visualization of the nuclei. Images 
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were acquired with an Olympus IX73 inverted microscope (Olympus America, Center Valley, PA) 
with a Hamamatsu ORCA-ER digital camera (Hamamatsu Corporation, Bridgewater, NJ) at 60x 
magnification. Image stacks (1344x1024 pixels; 0.2 m z-steps) of 100% of the tissue thickness 
were taken across the liver section and were stereologically selected using a grid of 100m2 frames 
spaced by 1000m. Image collection and processing were performed using Slidebook 6.0 
(Intelligent Imaging Innovations, Inc., Denver, CO) and Matlab (MathWorks, Natick, MA) 
software. First, an average projection of image stacks for a site was created to make a 2-
dimensional image of cells and their corresponding punctate mRNA grains. Then, a Gaussian 
channel was constructed for each channel by calculating a difference of Gaussians using sigma 
values of 0.7 and 2. Images were then separated into quantitative TIFF files of each individual 
channel and transferred to the HALO image analysis platform equipped with a fluorescent in situ 
hybridization add-on (Version 3.0, Indica Labs, Albuquerque, NM, USA). Using HALO software, 
DAPI-stained nuclei were quantified as any 40-355m2 object; puncta corresponding to Wnt7b 
and GFP were quantified as any 0.1-0.5m2 object. After determining the average puncta density 
levels for each probe (Wnt7b/wildtype: 0.43 puncta/DAPI-stained nucleus; GFP/wildtype: 1.28 
puncta/DAPI-stained nucleus), thresholds were set: 1 mRNA grain for Wnt7b, 4 mRNA grains for 
GFP. These thresholds represented ~3 times the smaller observed density level and were used as 
cutoffs for positive cells to eliminate false positives that occur due to nuclei neighboring positive 
cells. Therefore, a DAPI-stained nucleus was deemed Wnt7b+ if it contained a minimum of 1 
Wnt7b puncta within 5 m of the nucleus edge, and a cell was determined to be GFP+ if it contained 
a minimum of 4 GFP puncta within 5m of the nucleus edge.  
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4.3.8 Statistical Analysis 
Data was analyzed and presented as mean, standard deviation, and/or individual data points 
using Prism GraphPad 7.0c. P values were determined using appropriate analyses for the data. The 
tests used were two‐tailed Student t test and one‐way analysis of variance (ANOVA) or two-way 
ANOVA followed by an appropriate post-hoc test. P < 0.05 was considered statistically significant. 
4.4 Results 
4.4.1 Overexpression of Wnt7b in cholangiocytes induces cell proliferation independent of 
β-catenin signaling in vitro 
Previously, we showed that Wnt7b secreted by cholangiocytes induces proliferation in 
biliary cells through non-canonical Wnt signaling mechanisms (69). To verify these findings, we 
transfected small cell cholangiocytes (SMCCs) with control or Wnt7b plasmid, treated with β-
catenin or control siRNA, and measured cell proliferation. We were able to achieve 6.5-fold higher 
Wnt7b expression in cells transfected with the Wnt-carrying plasmid compared to control, while 
β-catenin expression was decreased by 75% compared to control (Figure 27). Using both 
thymidine incorporation and a colorimetric proliferation assay (WST-8), we confirmed that 
overexpression of Wnt7b promotes cholangiocyte proliferation in an autocrine manner (Figure 
28A-B), and that this process occurs independent of β-catenin activity, as knockdown of β-catenin 
does not affect cell proliferation induced by Wnt7b (Figure 28B). Furthermore, Wnt7b 
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overexpression in SMCCs reduces, rather than induces, β-catenin activity, as seen by the decrease 
in TOPFlash luciferase activity compared to cells without Wnt7b expression (Figure 28C).  
 
Figure 27. Quantitative RT-PCR analysis demonstrates Wnt7b overexpression and β-catenin suppression in 
SMCCs 
SMCCs transfected with Wnt7b plasmids have significantly increased expression of Wnt7B compared to cells 
transfected with control plasmid. SMCCs treated with β-catenin siRNA have significantly downregulated expression 




Figure 28. Overexpression of Wnt7B in SMCC culture induces cells proliferation independent of β-catenin 
activity. 
(A) Thymidine incorporation assay demonstrates that Wnt7b overexpression induces cholangiocyte proliferation in 
vitro. (B) Wst8 colorimetric assay demonstrates that Wnt7b overexpression induces cholangiocyte proliferation which 
is not inhibited in the presence of β-catenin siRNA. (C) Luciferase reporter of β-catenin activity, TOPFlash, 
demonstrates that Wnt7b overexpression does not induce β-catenin activity. ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 
0.0001. 
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4.4.2 Overexpression of Wnt7b induces an inflammatory phenotype in cultured 
cholangiocytes 
Cholangiocyte proliferation, which is observed during cholestasis, is often associated with an 
“activated” phenotype that is characterized by increased secretion of cytokines and growth factors 
(272). As Wnt7b induces cholangiocyte proliferation in an autocrine manner, we wanted to 
determine if it also induced production of these inflammatory mediators. Using a mouse cytokine 
ELISA kit, we found that TNF-α and IL-12 were upregulated significantly in conditioned media 
from Wnt7b-expressing SMCCs compared to those with control plasmid, while other cytokines 
and growth factors such as IL-1α, PDGF-BB and IL-6 trended higher as well (Figure 29). Thus, 




Figure 29. Wnt7b overexpression in cholangiocyte cell culture promotes upregulation of commonly altered 
cytokines 
ELISA analysis of (top graph) tumor necrosis factor alpha (TNFα), insulin-like growth factor 1 (IGF-1), vascular 
endothelial growth factor (VEGF), interleukin 6 (IL-6), basic fibroblast growth factor (FGFb), interferon gamma 
(IFNγ), epidermal growth factor (EGF), leptin, (middle graph) interleukin 1 alpha (IL-1α), interleukin 1 β (IL-1β), 
granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1-alpha (MIP-1α), stem cell factor 
(SCF), Rantes (Regulated on Activation, Normal T Expressed and Secreted), (bottom graph) platelet-derived growth 
factor (PDGF-BB), nerve growth factor β (β-NGF), interleukin 17A (IL-17A), interleukin 2 (IL-2), interleukin 4 (IL-
4), interleukin 10 (IL-10), resistin, and interleukin 12 (IL-12) show that Wnt7b overexpression promotes upregulation 
of common cytokines and growth factors. *P < 0.05. 
4.4.3 Wnt7b deletion in vivo improves biliary injury after 1 month of DDC exposure 
 In order to generate conditional KO of Wnt7b, Wnt7b-flox mice were bred with Krt19-cre 
mice to deplete Wnt7b expression in only cholangiocytes (CC), or with Alb-cre mice to delete 
Wnt7b expression in both hepatocytes and cholangiocytes (HC + CC). Both CC KO and HC + CC 
KO mice carry the Rosa-stopflox/flox-EYFP gene, which was used to assess efficiency of Wnt7b 
deletion from these cell populations. Figure 30A shows that approximately 50% of cholangiocytes 
in the CC KO mice were EYFP+, while 100% of cholangiocytes and hepatocytes were positive 
for EYFP in the HC + CC KO. RNAscope for Wnt7b also confirms a greater than 50% decrease 
in Wnt7b expression in cholangiocytes from CC KO mice (Figure 31). 
 102 
 
Figure 30. Confirmation of Wnt7b depletion in cholangiocyte-specific and liver-specific KO 
(A) EYFP (green), PanCK (red), and DAPI (blue) immunofluorescence and quantification shows that about 50% of 
cholangiocytes and 0% of hepatocytes are positive for EYFP expression in CC KO mice, indicating 50% efficiency 
of Wnt7b deletion in the cholangiocyte population. In HC + CC KO mice, 100% of cholangiocytes and hepatocytes 
have EYFP expression, indicating that Wnt7b knockout is complete in both cell populations. (B) Raw values from the 
quantitative RT-PCR analysis show loss of Wnt7b in KO mice (top). Cre-mediated removal of exon 3 from Wnt7bc3 
floxed mice creates the Wnt7bd3-null allele. Primers were designed to distinguish between functional Wnt7b protein 
(Wnt7b Exon 3) and the combination of Wnt7b and the untranslated null product (Wnt7b). Although Wnt7b expression 
increases in all genotypes after DDC diet, the expression is significantly less in CC KO and HC + CC KO than in WT. 
Additionally, the percentage of Wnt7b expression that contains exon 3 decreases in the KO after DDC by at least 40% 
(bottom). The persistence of full-length Wnt7b transcript in the KO indicates that either deletion from the cell types 
of interest is incomplete, or its loss is compensated for by other cell types. *P < 0.05, ∗∗P < 0.01, and ∗∗∗∗P < 0.0001. 




Figure 31. RNAscope for Wnt7b confirms deletion in CC KO 
Top, in situ hybridization (ISH) for Wnt7b RNA (red) shows that it is present in cholangiocytes of WT mice (left 
image), but not in cholangiocytes of CC KO mice (right). GFP RNA expression in both WT and CC KO confirms 
efficient recombination of Rosa-stopflox/flox-EYFP by tamoxifen in cholangiocytes. Representative images of zone 
1 are shown (original magnification, x600). Below, quantification of Wnt7b expression as a percentage of GFP+ cells 
shows that expression of Wnt7b in CC KO is about 30% that of WT. 
 
To assess the impact of Wnt7b loss in the setting of cholestatic liver disease, we then fed 
WT, CC KO and HC + CC KO mice control or DDC diet. Figure 30B shows that while Wnt7b 
expression increases in all genotypes after DDC diet, CC KO and HC + CC KO have significantly 
less full-length Wnt7b protein than WT, confirming loss of Wnt7b from these cell types. Analysis 
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of serum biochemistry after one month showed that CC KO and HC + CC KO mice fed DDC diet 
have significantly decreased alkaline phosphatase (ALP) levels compared to WT mice on DDC 
(Figure 32A), indicating that both types of KO have less biliary injury compared to WT mice. 
Interestingly HC + CC KO DDC-treated mice have normalized conjugated and total bilirubin 
levels compared to both WT and CC KO mice fed DDC diet, suggesting that the HC + CC KO 
mice have even less cholestatic injury compared to the other mice. However, hepatic injury is 
sustained across all three mouse models as indicated by serum alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) (Figure 32B). ALT is equally high in all three mouse models 
fed DDC diet, and AST also remains high among the three models, but HC + CC KO mice on 
DDC have significantly decreased AST levels compared to WT mice on DDC. Thus, rather than 
worsening the phenotype, deletion of Wnt7b protected mice from biliary injury during DDC-





Figure 32. Blood serum results indicate Wnt7b knockout improves biliary injury after 1 month of DDC 
exposure 
(A) Blood serum levels of ALP, conjugated bilirubin and total bilirubin show decreased biliary injury in mice lacking 
Wnt7b in both cholangiocytes only and cholangiocytes and hepatocytes when exposed to DDC diet for 1 month 
compared to WT mice. (B) Blood serum levels of ALT and AST indicate no changes in hepatic injury in mice lacking 
Wnt7b compared to WT mice on DDC diet for 1 month. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001 
4.4.4 Wnt7b knockout has no effect on parenchymal injury or fibrosis 
 To investigate parenchymal injury between the different genotypes, hematoxylin and eosin 
(H&E) stains of liver sections were performed. Both types of KO mice fed DDC diet have portal 
damage, including inflammation and ductular response, that is comparable to WT fed DDC (Figure 
33A). Therefore, Wnt7b knockout has no effect on cholestasis-induced parenchymal injury. To 
determine if lower ALP levels in Wnt7b KO mice on DDC diet correlate with decreased portal 
fibrosis, Sirius Red staining and quantification was used to assess the fibrotic content of these 
livers. Fibrosis in CC KO mice on DDC trended lower than in WT, while fibrosis in HC + CC KO 
mice on DDC was comparable to WT (Figure 33B). Therefore, we found no direct correlation 




Figure 33. Wnt7b KO has no effect on ductular response and fibrosis 
(A) H&E stains of liver sections show no difference in parenchymal injury and ductular response between WT, CC 
KO, and HC + CC KO mice fed DDC diet. (B) Sirius red stains of liver sections and quantification of the images show 
no difference in fibrosis between the mice fed DDC diet; however the CC KO mice trend toward decreased fibrosis. 
∗P < 0.05 and ∗∗∗P < 0.001. Original magnification, x200. 
4.4.5 Wnt7b regulates cholangiocyte proliferation and ductular response in vivo 
 Since we have previously shown that loss of Wnt secretion from hepatocytes and 
cholangiocytes leads to fewer CK19+Ki67+ cells after DDC treatment, we next assessed the 
mitogenic role of Wnt7b in vivo by quantifying the number of proliferating cell nuclear antigen 
(PCNA)-positive cholangiocytes after DDC (69). As expected, both CC KO and HC + CC KO 
mice on DDC diet have significantly fewer PCNA-positive cholangiocytes compared to WT mice 
on DDC diet (Figure 34), indicating that loss of Wnt7b directly affects cholangiocyte proliferation. 
Quantitative RT-PCR analysis of cholangiocyte markers epithelial cell adhesion molecule 
(EpCAM), cytokeratin 19 (CK-19), and sex-determining region Y-box transcription factor 9 
(Sox9) shows that CC KO mice on DDC diet have sustained expression of cholangiocyte markers 
compared to WT mice on DDC diet (Figure 35A). However, HC + CC KO mice on DDC diet 
trend toward decreased cholangiocyte marker expression compared to WT and CC KO on DDC 
diet (Figure 35A). These results are also mirrored in histological images of the early cholangiocyte 
marker A6. While CC KO mice have sustained ductular reaction compared to WT mice on DDC 
diet, HC + CC KO mice on DDC diet have significantly less ductular response compared to WT 
mice on DDC diet (Figure 35B-C). These results indicate that the suppressed ductular reaction 
seen in Wnt7b HC + CC KO is a result of decreased cholangiocyte proliferation. 
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Figure 34. Wnt7b knockout inhibits cholangiocyte proliferation 
Representative images and quantification of proliferation cell nuclear antigen (PCNA) show that Wnt7b knockout in 
both the cholangiocyte compartment and the cholangiocyte and hepatocyte compartment inhibits cholangiocyte 
proliferation in mice fed DDC diet. ∗P < 0.05, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Original magnification, 200x. 
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Figure 35. Wnt7b knockout suppresses ductular reaction and promotes hepatocyte expression of 
cholangiocyte markers 
(A) Quantitative RT-PCR analysis of cholangiocyte markers EpCAM, CK-19, and Sox9 show a significant decrease 
in EpCAM and a trend toward lower CK-19 and Sox9 in HC + CC KO compared to WT after DDC. (B) su (C) 
Quantification of A6 positive cholangiocytes shows that HC + CC KO on DDC diet have significantly decreased 
ductular reaction compared to WT on DDC diet. D) Quantification of A6 positive hepatocytes shows that that HC + 
CC KO on DDC diet have significantly more A6 positive hepatocytes compared to WT and  CC KO on DDC diet. ∗P 
< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Original magnification, 100x. 
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4.4.6 Wnt7b knockout promotes hepatocyte-to-cholangiocyte reprogramming 
 We also found A6 positive hepatocytes in our mice exposed to DDC diet. Interestingly CC 
KO mice on DDC have more A6 positive hepatocytes than WT mice on DDC diet, though the 
number is not significant (Figure 35D). However, HC + CC KO mice on DDC have a significant 
amount of A6 positive hepatocytes compared WT and CC KO mice on DDC diet (Figure 35D). 
These results indicate that loss of Wnt7b may promote hepatocyte expression of cholangiocyte 
markers, or hepatocyte-to-cholangiocyte reprogramming, when mice lacking Wnt7b in 
cholangiocyte and hepatocyte compartments are exposed to DDC diet. 
 
4.4.7 β-catenin activation is increased in livers that lack Wnt7b in hepatocytes and 
cholangiocytes 
 Loss of Wnt7b may result in compensatory upregulation of other Wnts expressed during 
cholestasis. One of these is Wnt7a, which induces Sox9 expression in a β-catenin-dependent 
manner (69). To determine if upregulation of Wnt7a might be contributing to hepatocyte 
reprogramming, we examined its expression and found that DDC induced Wnt7a in all three mouse 
models; however, it was not significantly increased in either CC KO or HC  
+ CC KO compared to WT (Figure 36A). Interestingly, however, non-phosphorylated β-catenin, 
which is an indicator of active canonical Wnt signaling, was higher in HC + CC KO on DDC 
compared to the same mice on normal diet, whereas phosphorylation of β-catenin at Serine 675, 
which occurs via the cAMP-dependent protein kinase A (PKA) pathway, was unchanged (Figure 
36B) (30). Thus, the increased number of A6-expressing hepatocytes correlates with activation of 
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canonical β-catenin in HC + CC KO (and to a lesser extent in the CC KO), and this phenomenon 
is independent of Wnt7a. 
 
Figure 36. Wnt7a expression and β-catenin activity is upregulated in mice fed DDC diet 
(A) Quantitative RT-PCR analysis of Wn7a shows that DDC diet induces expression of Wnt7a in all three 
genotypes. (B) Western blot and densitometry analyses for phosphorylated (S675), non-phosphorylated active, and 
total β-catenin shows that CC KO mice and HC + CC KO mice fed DDC diet trend toward an increase in Wnt-
dependent active β-catenin. *P < 0.05, **P < 0.01. 
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4.5 Discussion 
Previous studies have shown that in kidney cells macrophage-derived Wnt7b is critical for 
regeneration after injury by overcoming a G2 arrest in the cell cycle and preventing apoptosis 
(184). Additionally, Wnt7b is expressed in cholangiocarcinoma cells, and correlates with disease 
progression (269, 273). Though in vitro studies, we have also shown that Wnt7b plays a role in 
cholangiocyte proliferation during cholestatic liver injury (69). As expected, when Wnt7b was 
deleted from either cholangiocytes alone or hepatocytes and cholangiocytes in vivo, these KO mice 
had decreased numbers of proliferating cholangiocytes during cholestasis. Unexpectedly, despite 
our initial hypothesis that impaired ductular response would exacerbate cholestatic disease 
progression in response to DDC, Wnt7b KO mice are actually protected from biliary injury. There 
is almost a direct relationship between Wnt7b expression and ALP levels in serum; as Wnt7b is 
deleted from more cell types biliary injury improves. However, this decrease in injury is not due 
to the cholangiocytes’ inability to proliferate, but instead related to hepatocytes’ ability to 
transdifferentiate into a biliary-like phenotype.  
It is well known that hepatocytes are remarkably plastic. When the biliary epithelium is 
critically injured, hepatocytes can function as “facultative stem cells,” and undergo reprogramming 
from one epithelial cell type to the other to facilitate repair (216, 217). Typically, in rodent models, 
mature hepatocytes transdifferentiate into either fully-functional cholangiocytes or a 
cholangiocyte-like phenotype when there is extensive injury and resident cholangiocytes lose 
functionality and are incapable of adequately proliferating to compensate for the injury (218-221). 
Similar results have also been observed in humans. Hepatocytes from both pediatric and adult 
cholangiopathy patients have been reported to express the ductal marker OV-6 (227, 228), 
cholangiocyte-specific cytokeratins(229-231), and biliary transcription factors (222, 224). These 
 113 
findings from both rodents and humans suggest that during biliary injury the number of 
hepatocytes expressing biliary markers increases over time. As cholestasis progresses, more and 
more hepatocytes compensate for the damage to and loss of the biliary epithelium. 
In our models we found that as more cell types lost Wnt7b hepatocytes became more likely 
to express cholangiocyte markers. In WT mice on DDC diet biliary injury is repaired through 
Wnt7b driven cholangiocyte proliferation, and hepatocytes remain hepatocytes. CC KO mice have 
a few reprogrammed hepatocytes, which once converted to cholangiocytes will self-renew, since 
hepatocyte-derived cholangiocytes in the CC KO mice are able to express Wnt7b (Figure 37). In 
HC + CC KO mice even more hepatocytes are becoming biliary-like because the hepatocyte-
derived cholangiocyte do not express Wnt7b; therefore, they cannot self-renew and more 
hepatocyte-derived cholangiocytes are needed to help repair the injured bile ducts (Figure 37). 
These findings are important because typically, hepatocytes do not undergo cellular 
reprogramming until biliary injury is so extensive that cholangiocytes are unable to compensate. 
Our study shows that by blocking cholangiocyte proliferation we can induce hepatocytes to begin 
reprogramming earlier to alleviate injury.  
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Figure 37. Schematic of how Wnt7b KO might promote hepatocyte-to-cholangiocyte reprogramming 
(A) Cholangiocytes in WT mice exposed to biliary injury attempt to self-renew through Wnt7b expression to repair 
injured ducts. (B) In CC KO mice cholangiocytes lacking Wnt7b are unable to proliferate at an efficient rate, so a few 
hepatocytes begin expressing biliary markers; these cells then self-renew to repopulate the injured ducts. (C) In HC + 
CC KO mice cholangiocytes lacking Wnt7b are unable to proliferate, so hepatocytes become cholangiocyte-like. 
However, these hepatocyte-derived cholangiocytes are also unable to proliferate due to Wnt7b KO, so more 
hepatocytes must transdifferentiate to alleviate biliary injury. 
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Both Wnt7a and Wnt7b, along with Wnt10a, are highly expressed in models of cholestasis 
(69, 78). As Wnt7a induces cellular reprogramming in neighboring hepatocytes in a -catenin-
manner, we hypothesized a compensatory increase in Wnt7a in our Wnt7b KO models (CC or HC 
+ CC) that might account for the increased number of reprogrammed hepatocytes. Interestingly, 
we do not see a further induction of Wnt7a in either KO. However, we did note an increase in non-
phosphorylated, activated -catenin, which has been shown previously to induce a biliary 
phenotype in hepatocytes (69, 180). Therefore, we believe that loss of Wnt7b activates -catenin 
through some as-yet unknown mechanism to promote hepatocyte reprogramming. Indeed, 
TOPflash activity data suggests that overexpression of Wnt7b in cholangiocytes suppresses -
catenin activity, consistent with previous studies that demonstrated non-canonical Wnts can 
antagonize -catenin activation (274-276). Further mechanistic studies will be needed to determine 
if the stoichiometry of Wnt7b/Frizzled receptor complex may out-compete binding of canonical 
Wnts in cholangiocytes during cholestasis. 
Beyond its participation in cell cycle and repair processes, little else is known about the 
biological function of Wnt7b in the liver. We have shown that overexpression of Wnt7b in a 
cholangiocyte cell line stimulates secretion of certain cytokines associated with inflammation. 
During cholestasis cholangiocytes abandon a differentiated phenotype to repair the bile duct (181). 
Under normal conditions, cholangiocytes do not produce an abundance of growth factors and 
cytokines, but after exogenous or endogenous insult they acquire the ability to secrete factors that 
act in an autocrine and paracrine manner to promote remodeling (272). However, reactive 
cholangiocytes can also contribute to progression of liver injury by activating hepatic stellate cells 
and attracting immune cell populations that generate a persistent inflammatory response. Our data 
suggests that Wnt7b could be one of the switches driving this proliferative/inflammatory 
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phenotype during cholestasis, with unfavorable consequences for disease progression. Modulating 
this axis to block cholangiocyte proliferation and promote hepatocyte transdifferentiation could 
provide a novel treatment that would alleviate biliary injury in patients with PSC or other 
cholangiopathies. 
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5.0 Concluding Remarks and General Discussion 
5.1 Significance 
Though cholestatic liver diseases, such as primary sclerosing cholangitis (PSC), have a 
lower incidence than other causes of chronic liver diseases, such as viral hepatitis, alcoholic 
hepatitis, and non-alcoholic fatty liver disease, they still account for 8-11% of all liver transplants 
performed each year (277-279). The lack of donor organs and mortality of patients awaiting 
transplant, means alternative treatments for cholestatic liver disease patients is greatly needed 
(280). Therefore, the ability to promote healthy bile duct growth and regeneration in PSC patients 
could be the key in creating a new treatment, alleviating the needs for donor organs. In this 
dissertation, we determined that the Mdr2 KO mouse model has decreases levels of thyroid 
hormone receptor beta which causes hepatocytes to retain toxic bile injuring the liver. These 
findings could indicate that patients with PSC may also suffer similar side effects that cause 
exacerbated hepatic injury when treated with GC-1. This could be important knowledge to keep in 
mind when considering GC-1 as a treatment for PSC patients, as this treatment may put patients 
at higher risk of developing liver failure. Additionally, we have identified two potential methods 
to activate hepatocyte-to-cholangiocyte transdifferentiation and further elucidated the role that 
Wnt7b plays in cholangiocyte proliferation. These findings are both significant and exciting 
because they could help establish a foundation for new treatments for PSC. 
Both hepatocytes and cholangiocytes are able to function as a type of “facultative stem 
cells,” and undergo reprogramming from one cell type to the other (216, 217). Specifically 
hepatocyte-to-cholangiocyte reprogramming has been well recorded in vitro in hepatic organoids 
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(222, 223),  in vivo in both mice and rats (218-221, 223-226), and in vivo in human patients (222, 
224, 227-231). However, despite this knowledge the mechanisms through which this 
reprogramming occurs are poorly understood. Excitingly, our findings indicate that β-catenin 
signaling is a driver of this reprogramming. We also found that whenWnt7b induced cholangiocyte 
proliferation is blocked during cholestatic injury, β-catenin activates and induces hepatocyte 
reprogramming as well. These findings together could help to develop a treatment for PSC patients 
that blocks injured cholangiocyte proliferation through inhibiting Wnt7b signaling and promoting 
hepatocytes to reprogram using β-catenin activation to create healthy bile ducts, alleviating 
cholestatic injury.  
5.2 Future Directions: Wnt/β-catenin Driven Hepatocyte-to-Cholangiocyte 
Transdifferentiation 
The current body of literature makes it well known that both hepatocyte and cholangiocytes 
exhibit remarkable plasticity, and under specific serious hepatic or biliary injury the two cell types 
can convert to one another in an attempt to alleviate said injury. However, the pathways involved 
in specifically hepatocyte-to-cholangiocyte transdifferentiation have not been fully studied. It has 
been found that these reprograming events involve a number of regenerative pathways including 
HGF signaling via MET, EGFR signaling, and potentially canonical Wnt/β-catenin signaling (69, 
177, 180, 217, 281). Our findings that β-catenin signaling induces hepatocyte-to-cholangiocyte 
transdifferentiation in our mouse models further supports this knowledgebase. However, the Wnt 
ligand that induces this canonical signaling and hepatocyte reprogramming has not been fully 
determined. There is evidence that Wnt7a could be the ligand that induces this hepatocyte-to-
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cholangiocyte transdifferentiation through canonical Wnt signaling, but further research is needed 
to confirm this hypothesis (69). Therefore, is it important in the future to determine whether 
Wnt7A, or another Wnt ligand, drives this canonical Wnt signaling induce hepatocyte-to-
cholangiocyte conversion. 
It also remains unknown whether hepatocyte-derived cholangiocytes fully commit to a 
cholangiocyte phenotype and remain cholangiocytes or revert back to hepatocytes after injury is 
reversed (225). Studies have shown that hepatocyte-derived cholangiocytes incorporate into 
biliary ductules, but no studies have compared their functionality to that native cholangiocytes 
(221, 224, 225, 232). Therefore, it would be necessary to test the incorporated hepatocyte-derived 
cells functionality compared to native cholangiocytes and determine if these cells remain 
cholangiocytes after cholestatic injury is alleviated. All of these questions will be undoubtedly 
answered in the future. Once we determine which Wnt ligand induces β-catenin driven hepatocyte 
reprogramming and how the newly derived cholangiocytes will act in the bile ducts, future patients 
with PSC will likely have a treatment option that does not rely on whole liver transplants. 
5.3 Future Directions: Wnt7b Driven Cholangiocyte Proliferation 
As we learn more information about the roles Wnt signaling plays in the liver, it is clear 
canonical Wnt signaling is involved in almost every aspect of liver function, from generation to 
metabolism to regeneration. Despite all that is known about Wnt/β-catenin signaling in the liver, 
there is still much to be learned about Wnt signaling, both canonical and non-canonical, in the 
liver, specifically in reference to the bile ducts. In our study we were able to further the knowledge 
of Wnt7b’s role in cholangiocyte proliferation. However, very little is known about which Wnt 
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ligands interact with which Frizzled receptors in many cell types and if these interactions are 
altered in certain diseases. Elucidating this information becomes even more complex when faced 
with the knowledge that there are 19 Wnt ligands and 10 Frizzled receptors in the mammalian 
genome (57, 58). Therefore, determining which Frizzled receptor or receptors Wnt7b interacts 
with to induce cholangiocyte proliferation during cholestatic injury could be difficult to determine. 
Additionally, canonical Wnt signaling is well studied and understood in liver development, 
homeostasis, and regeneration; however, non-canonical Wnt signaling, which Wnt7b signals 
through to induce cholangiocyte proliferation, is not. This is further compounded with the fact that 
there are multiple non-canonical pathways through which Wnts can signal, making it trickier to 
study non-canonical Wnt signaling (46, 47, 51, 52). Finally, the role of non-canonical Wnt7b 
signaling in the pathobiology of cholestatic liver disease, such as PSC, in human patients will need to 
be investigated further as well. Undeniably, future research will fully identify the exciting role Wnt7b 
and non-canonical Wnt signaling play in in bile duct pathobiology and regeneration. 
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